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Triple Negative Breast Cancer (TNBC) is highly invasive and metastatic with 
approximately 15% of patients developing liver metastases. The primary treatment of metastatic 
TNBC is chemotherapy, however, there is an increased chance of resistance to this therapeutic 
technique. If Breast Cancer Liver Metastasis (BCLM) is left untreated most patients survive only 
4 to 8 months with a very rare 5-year survival. Therefore, it is imperative to analyze markers and 
molecular pathways that TNBC cells use to progress, invade, and metastasize to the liver. The 
aim of this study was to examine the overexpression of angiopoietin-like 4 (ANGPTL4) in 
TNBC cells in vitro and in vivo. 
 Experimentally, ANGPTL4 mGFP was overexpressed in the MDA-MB-231(TNBC) cell 
line using lentiviral-mediated transduction. This expression was then confirmed using western 
blot analysis, ELISA, and fluorescence microscopy.  
The intracellular localization of ANGPTL4, Tat-interactive protein p60 (Tip60) and 
Aurora Kinase A (AURKA) were evaluated by subcellular fractionation, western blot analysis, 
and immunofluorescence microscopy. This study showed that ANGPTL4 is localized in the 
nucleus and is a chromatin-bound protein. This implies that ANGPTL4 could potentially bind to 
DNA and affect transcriptional regulation. In addition, the findings of this study showed that 
TIP60 and AURKA, predictive interactors of ANGPTL4 are in the nucleus and 
compartmentalizes with ANGPTL4. This suggests that their association with ANGPTL4 could 
drive tumor progression and metastases. A mammosphere assay was performed to evaluate the 
“stemness” capability of TNBC cells expressing ANGPTL4. The results of the mammosphere 
assay promote the expansion of the cell colonies in the ANGPTL4 mGFP overexpression in the 
TNBC cell line. This indicates that the ANGPTL4 mGFP expressing cell line have stem-cell like 
renewal potential in vitro. In this study, the soft agar colony formation assay was performed to 
measure the prospective tumorigenic ability of the ANGPTL4 mGFP cell line. The ANGPTL4 
mGFP cell line exhibited enhanced anchorage-independence which speaks to the possible 
tumorigenic capacity of the cells to be used in in vivo studies.  
Subsequently, a mouse model was used to evaluate the metastatic ability of ANGPTL4 
primed TNBC cells in vivo. The findings show that MDA-MB-231 ANGPTL4 mGFP cell line 
had bigger primary tumors compared to the mGFP cell line expressing endogenous ANGPTL4. 
Furthermore, ANGPTL4 mGFP cell line resulted in more metastatic lesions on the liver 
compared to the MDA-MB-231 mGFP cell line. Collectively, these findings imply that 
ANGPTL4 is a driver of TNBC proliferation and metastases and therefore could be used as a 
therapeutic target for TNBC treatment. 
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I.1 The Molecular Subtypes of Breast Cancer 
Breast cancer is the world’s most diagnosed disease ( (Breast cancer now most common 
form of cancer: WHO taking action, 2021) and, because of its heterogeneous nature, evidence 
suggests that with different histopathological and biological features there are distinct behaviors 
that lead to different treatment responses.  Due to these responses, specific therapeutic approaches 
should be given for breast cancer treatment ( (Blows, et al., 2010).Thus, the accurate grouping of 
breast cancers into clinically relevant subtypes is the first important step for therapeutic decision-
making ( (Dai, et al., 2015). 
Consequently, there are five major subtypes of breast cancer ( (Molecular Subtypes of 
Breast Cancer, 2021) determined by the presence or absence of the hormone receptor (HR) and 
the human epidermal growth factor receptor (HER2/neu). The hormone receptor can be an 
estrogen receptor or a progesterone receptor. HR+ (positive) means that tumor cells have 
receptors for the hormone estrogen or progesterone that promote the growth of HR+ tumors, 
whereas HER2+ means that tumor cells produce high levels of a protein called HER2/neu, which 
has been associated with aggressive types of breast cancer. In addition, high or low levels of the 
nuclear protein Ki-67 is used to detect how quick cells grow (Li, Jiang, Chen, & Zheng, 2015), 
(Sun & Kaufman, 2018). 
The first subtype of breast cancer is luminal A, and it has the tendency to progress slowly 
and, as a result, has the best prognosis. This type of breast cancer is HR+, HER2 – (negative), 
and has low levels of the protein Ki-67. Second, luminal B breast cancer is considered HR+, and 
either HER2+ or HER2- with high levels of Ki-67 (National Institute of Health. Surveillance, 
Epidemiology, and End Results Program , 2017). Aggressive basal-like, triple-negative breast 
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cancer (TNBC) is HR- and HER2-  (Keam, et al., 2011), (National Institute of Health. 
Surveillance, Epidemiology, and End Results Program , 2017), (Soliman, Khalil, & Antonia, 
2014). In addition, HER2-enriched breast cancer is hormone-receptor negative and HER2+, and 
they tend to grow faster than luminal cancers and have a potentially worse prognosis, (National 
Institute of Health. Surveillance, Epidemiology, and End Results Program , 2017), (Soliman, 
Khalil, & Antonia, 2014). However, they are usually successfully treated with targeted therapies 
aimed at the HER2 protein, such as Herceptin. Furthermore, normal-like breast cancer is similar 
to luminal A disease. However, its prognosis is slightly worse than luminal A cancer’s prognosis 
(Herr, et al., 2019) 
 
Table 1.1 - Summary showing the characterizations of the breast cancer subtypes and the 




















Luminal A + + - Low 94.3 
Luminal B + + +/- High 90.5 
TNBC - - - High 76.9 
HER2-
enriched 
- - + High 84.0 
Normal-like + + - Low 91.0 
 
I.2 Triple Negative Breast Cancer Overview  
  TNBC is defined by the absence of an estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2. It is estimated that out of the worldwide breast cancer 
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burden, approximately 170,000 cases are TNBC and account for 10-20% of invasive breast 
cancers ( (Boyle, 2012), (Foulkes, Smith, & Reis-Filho, 2010), (Kumar & Aggarwal, 2016). 
TNBC incidence has been associated with women of color, mutations in breast cancer gene 
susceptibility protein 1/2 (BRCA 1/2), women of Jewish ancestry, onset at a younger age, 
higher-grade tumors, more advanced tumor grade at diagnosis, and increased recurrence ( 
(Byrski, et al., 2009) (Comen, et al., 2011), (Dent, et al., 2007), (Foulkes, et al., 2003), (Kirk, 
2010) (Lundqvist, Andersson, Ahlberg, Nilbert, & Gerdtham, 2016), (Mavaddat, et al., 2012), 
(Musolino, et al., 2007), (Prat & Perou, 2011), (Philipovskiy, Corral, Dwivedi, Heydarian, & 
Gaur, 2019), (Turner, Tutt, & Ashworth, 2004). 
Epidemiological studies have reported that TNBC is more common in women of African, 
Hispanic, and Jewish ancestry ( (Bauer, Brown, Cress, Parise, & Caggiano, 2007), (Carey, et al., 
2006), (Comen, et al., 2011), (Jiagge, et al., 2016), (Kohler, et al., 2015), (Philipovskiy, Corral, 
Dwivedi, Heydarian, & Gaur, 2019), (Sørlie, et al., 2001). Additionally, multiple findings have 
examined higher prevalence and incident rates, worse clinical outcomes, and mortality rates of 
TNBC in African American, Hispanic and Jewish women compared to TNBC in European 
American women (Bonotto, et al., 2014), (Clark, Rodriguez, Snyder, Hankins, & Boehning, 
2012), (DeSantis, et al., 2019), (Hunter, 2000), (Siegel, Miller, & Jemal, 2016).  
The frequency of TNBC in women of color with low survival could be accounted for by 
genetic risk and socioeconomic factors. Although (Stewart, et al., 2019) reported that African-
American women with TNBC showed enhanced BRCA1 gene, BRCA1 is a lower pathogenic 
variant compared to the increased BRCA1 mutation incidences in European American women 
(Nanda, et al., 2005), (Qian, et al., 2017), (Stewart, et al., 2019). This is due to the abundance of 
sequence variations associated with the BRCA1 gene in African-American women which 
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inhibits BRCA1 function at a lower rate than in European women (Szabo & King, 1997). In 
addition, (Santonja, et al., 2018) reported that Hispanic women with breast cancer have the 
highest incidence of pathogenic BRCA1 mutations and this genetic factor may heavily contribute 
to the high mortality rates of women with TNBC. (Kwon, et al., 2010) found that more than half 
of the Jewish women in their study with TNBC carried a BRCA founder mutation. As a result, 
there was a prevalence of BRCA mutations among young and older Jewish women with 
TNBC. Furthermore, there was a significant proportion of Jewish women with TNBC and 
BRCA2 mutations, meaning that TNBC was not limited to only BRCA1(Comen, et al., 2011). 
In addition, numerous socioeconomic factors that influence the access to standard care, 
novel treatments, limited healthcare, and inclusion in clinical trials contribute to the overall poor 
prognosis of African American and Hispanic women diagnosed with TNBC (Hossain, et al., 
2019), (Lara-Medina, 2011), (Patel, et al., 2010), (Siddharth & Sharma, 2018), (Sturtz, Melley, 
Mamula, Shriver, & Ellsworth, 2014), (Elrafei, et al., 2014). Many women of color with breast 
cancer have subpar access to appropriate treatment; as a result, there is delayed diagnosis and a 
greater tumor burden. The delay in diagnosis could be because of little or no hospitals near the 
locations where these women reside, the inability to seek a leave of absence from work due to a 
lack of affordability, and no or little access to health insurance (Hossain, et al., 2019), (Parise & 
Caggiano, 2018).  Latina women are more likely to be uninsured, have lower educational 
accomplishments, and have higher poverty rates than European American women (Chlebowski, 
et al., 2005). Language, cultural, and financial barriers also play a significant contribution to a 
higher mortality rate of TNBC in Hispanic Women (Mack, Pavao, Tabnak, Knutson, & 
Kimerling, 2009). Thus, the inaccessibility to health care leads to limited access to standard care 
and timely treatment and as result poor overall survival. Moreover, women of color with breast 
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cancer generally have a lower participation in clinical trials than their white counterparts, due to 
the poor communication and language barriers regarding these trials and their lack of confidence 
and trust in medical research. This could be because of the poor care in previous clinical 
experiments; for example, the treatment of African-American men in the infamous Tuskegee 
Syphilis Study and the study of genetic etiology of aggressive behavior in African-American 
boys (Alsan & Graziani, 2019), (Scharff, et al., 2010), (Shavers & Brown, 2002), (US Preventive 
Services Task Force, et al., 2019). 
TNBC has a more aggressive clinical route with an early age of presentation compared to 
the other breast cancer subtypes. The mean age at diagnosis is significantly younger for the 
TNBC group at 53.0 years compared with other groups at 57.7 years (Dent, et al., 2007). 
Similarly, patients in the TNBC group had a 2-fold increase in grade III tumors compared to the 
other breast cancer subtypes, and the mean tumor size was larger in the triple-negative group 
than in any group (Dent, et al., 2007). (Collett, et al., 2005) evaluated cancers diagnosed in a 
screening program between 1996 and 2001 and found that TNBC was more likely than other 
breast cancers to present in the interval between regular mammograms. Also, (Brown, et al., 
2008) reported that TNBC tumors were significantly larger, and they were more likely to present 
as stage II or III of the disease. 
Most TNBCs are high grade invasive ductal carcinomas (IDCs) with characteristics such 
as apocrine differentiation, breast cancer with medullary features, and metaplastic breast 
carcinomas (MBCs) (Foulkes, et al., 2010). TNBCs with apocrine differentiation demonstrate the 
same growth pattern as IDC, differing only in their cytological appearance. The cells are 
characterized by abundant eosinophilic granular cytoplasm (Type A) and multiple nucleoli 
(Vranic, et al., 2010), (Yerushalmi, Hayes, & Gelmon, 2009). Thus, these apocrine cells can 
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proliferate into atypical lesions. TNBC with medullary features display clearly defined oval 
borders, a syncytial growth pattern, and lymphocytic infiltration with high mitotic activity 
(Kleer, 2009) (Lakhani, Ellis, Schnitt, Tan, & van de Vijver, 2012)  (Pedersen, Schiødt, Holck, & 
& Zedeler, 1990). Lastly, MBCs encompass a range of tumors with squamous or mesenchymal 
differentiation (Weigelt, et al., 2008). These tumors are most often high grade, with easily visible 
abnormal nuclear size and shape with increased mitotic activity. TNBCs with MBCs are resistant 
to chemotherapy and have a worse outcome compared to the other subtypes (Jung, et al., 2015) 
TNBC is known to have frequent recurrence after diagnosis and more aggressive visceral 
metastases which are more likely to occur in the lungs, brain, liver and less likely to spread to the 
bone  (Criscitiello, Azim, Jr, Linn, & Sotiriou, 2012), (Smid, et al., 2008). A Canadian series 
reported by (Dent, et al., 2007) evaluated over 1,500 women diagnosed with TNBC which 
showed a higher proportion of local and distal recurrence and death compared to non-TNBC 
patients. 
 
Chapter I.3 Triple Negative Breast Cancer Therapeutic Treatment Options 
Patients with TNBC derive no advantages from molecularly targeted treatments, such as 
endocrine therapy and Herceptin, because they lack the proper targets for these drugs. The 
standard approach to treat TNBC has been to use cytotoxic therapeutics, but the chemotherapies 
lack the desired selectivity and chemoresistance is a significant problem, demonstrating 90% of 
drug failures in metastatic cancers (Longley & Johnston, 2005). Initially, TNBC patients respond 
well to neoadjuvant treatments. Unfortunately, there is a possibility of relapse in patients in the 
first 5 years in comparison with other breast cancer subtypes (Cinkaya, Akin, & Sengul, 2016). 
Nevertheless, neoadjuvant chemotherapy remains the standard care for TNBC patients (Rouzier, 
et al., 2005). Currently, neoadjuvant anthracycline–cyclophosphamide (AC-scheme) 
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chemotherapy treatment appears to be more efficient, although there have been reports on 
resistance developed for these drugs (Geisler, et al., 2001).  
In addition, use of anthracyclines (A), taxanes (T), or platinum compounds are also 
utilized as adjuvant therapy which works to disrupt cancer cell survival (Liedtke, Mazouni, Hess, 
André, & Pusztai, 2008), (Petrelli, De Stefani, Raspagliesi, Lorusso, & Barni, 2014), (Silver, et 
al., 2010). (Jones, et al., 2009) published that four-cycle regimens of docetaxel and 
cyclophosphamide are more effective than four-cycle regimens of anthracycline and 
cyclophosphamide which resulted in longer overall survival of TNBC patients. As a result, the 
use of non-anthracycline taxane-containing regimens has become more common. Adjuvant 
chemotherapy reduces the risk of recurrence, particularly in patients with tumors greater than one 
centimeter. However, A+T treatment increases the risk of cardiac toxicity in older patients 
(Schreiber, et al., 2020). 
Breast-conserving surgery has been studied as a therapeutic approach to treat TNBC. 
(Frasci, et al., 2009) evaluated tests to determine the prognostic effects of mastectomy over 
lumpectomy. In TNBC the sole choice of the surgical approach does not improve the prognosis 
or inhibit the local tumor recurrence (Freedman, Anderson, Li, & Nicolaou, 2009). A 
lumpectomy followed by radiation therapy (RT) could be an option.  However, in TNBC the 
benchmark treatment is neoadjuvant therapy, and it is preferred before surgery.  
Similar to breast surgery RT is part of the treatment regimen for TNBC, though there are 
drawbacks (Dawood, Broglio, Buzdar, Hortobagyi, & Giordano, 2010). TNBC is considered an 
aggressive subtype which is susceptible to radiotherapy and evidence points out that TNBC 
BRCA1 abnormal expression is highly radiosensitive (Abdulkarim et al., 2011). Although 
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radiotherapy after mastectomy can improve the results of TNBC, radioresistance is a major 
contributor to radiotherapy failure (He, et al., 2018), (Yin, et al., 2016). 
Additionally, the use of small molecules to enhance specific delivery and action toward 
the direct molecular target has been analyzed as a potential treatment option. Aptamers are 
molecules made up of nucleotides, generally in a range of 50 deoxyribonucleic acid (DNA) or 
ribonucleic acid (RNA) bases, that are evolved to bind to specific molecular targets. Their small 
size makes them suitable to reach molecular targets, therapeutic targets, protein complexes, and 
cancer cells  (Kulbachinskiy, 2007). Aptamers are easy and cheap to produce but their 
degradation in the bloodstream is a clear disadvantage. 
TNBC has the worst outcome for immune response treatment because of the higher 
expression of the metastasis promoting genes as well as the decreased expression of metastasis 
inhibiting genes. Consequently, within the TNBC tumor microenvironment, there are latent 
lymphocytes and antigen-presenting cells that do not respond correctly to tumor cells. Recently, 
strategies have been implemented to “push” these cells from their quiescent state and initiate a 
response that slows the progression of the tumor (Li, Qiu, Lu, Jiang, & Wang, 2018), (Ruffell, 
Affara, & Coussens, 2012). It is suggested that cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
helps in the downregulation of the immune response (Linsley, et al., 1994). So, the current 
efforts are directed to activate immune system response by using CTLA-4 inhibitors such as 
ipilimumab. The challenge, however, is that CTLA-4 inhibitors aggressively activate T-cells, 
generating different systemic adverse effects (Maker, et al., 2005). 
 DNA damage of the genome occurs because of base changes, replication errors, free 
radicals, chemical agents, cancer therapeutics, and UV radiation (Friedberg, et al., 2006), (Ward, 
1988). Double-stranded DNA breaks (DSBs) caused by these agents are detrimental to 
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eukaryotic cells so, two DNA repair mechanisms are used: nonhomologous end-joining and 
homologous recombination (HR). DSBs produced by collapse of the replication fork are 
primarily repaired by HR because the broken ends use homologous sequences from sister 
chromatids or regions on the chromosomes to prime repair synthesis (Chen, Yang, & Pavletich, 
2008) (Rothstein, Michel, & Gangloff, 2000).  Thus, HR is a DNA metabolic process that plays a 
vital role in preserving the genome and providing critical support for DNA replication and 
telomere maintenance (Degrassi, Fiore, & Palitti, 2004), (Shrivastav, De Haro, & Nickoloff, 
2008). 
Moreover, HR is dependent on functional BRCA1/2 pathways since BRCA maintains 
genome stability by regulating HR according to the type of DNA damage (Prakash, Zhang, Feng, 
& Jasin, 2015), (Sadeghi, et al., 2020). Germline mutations in either the BRCA1/2 genes are 
associated with a high risk of developing TNBC (Ahn, Kim, Kim, & Jeong, 2016), (Chen, et al., 
2018), (Evans, et al., 2011), (Greenup, et al., 2013). When HR is dysfunctional, repair shifts 
toward an alternate DNA repair mechanism dependent on a class of enzymes called poly-
adenosine diphosphate-ribose polymerase (PARP). PARPs are a family of enzymes involved in 
cellular processes such as genomic stability, DNA repair, cell cycle progression, and apoptosis 
(Schreiber, et al., 1995), (Skidmore, et al., 1979). PARP-1 functions as a DNA-binding protein, 
with nuclear localization which associates with DNA strand breaks as part of the base excision 
repair process (Helleday, Petermann, Lundin, Hodgson, & Sharma, 2008), (Plummer, et al., 
2008). 
As such, there were preclinical studies that justified the use of PARP inhibitors and 
highlighted PARP inhibitors as a promising targeted therapy for aggressive TNBC (Mahany, et 
al., 2008). The optimal treatment strategy is the combination of PARP inhibition with either 
10 
cytotoxic DNA-damaging chemotherapeutic agents or with molecular targeted agents that also 
impair mechanisms of DNA repair since monotherapy with PARP inhibitors is unlikely to induce 
cancer cell death in BRCA-proficient tumors (Alli, Sharma, Sunderesakumar, & Ford, 2009), 
(Hastak, Alli, & Ford, 2010), (Papadimitriou, Mountzios, & Papadimitriou, 2018). 
However, there are several challenges associated with PARP inhibitor TNBC treatment. 
These challenges are establishing optimal therapy to couple with PARP, having a defined 
treatment when treating aberrant TNBC metastases, effective administration of cytotoxic 
therapies, defining the population most likely to respond to PARP inhibition in the TNBC 
community, and analyzing candidate biomarkers to predict how patients respond to treatment 
(Dent, et al., 2009), (Edwards, et al., 2008) (Gelmon, et al., 2010), (Rodríguez-Pinilla, et al., 
2006). As a result, investigators must further define TNBC patients most likely to respond to 
PARP inhibitors since these drugs are transitioning to adjuvant settings and long-term toxicities 
to normal tissues have not yet been characterized for prolonged DNA repair suppression. 
Trophoblast cell surface antigen 2 (TROP-2) is a glycoprotein which is overexpressed in 
human cancers and, has shown to be a promising therapeutic target (Lipinski, Parks, Rouse, & 
Herzenberg, 1981). TROP-2 overexpression in metastatic TNBC accelerates the cancer cell cycle 
and drives cancer growth. This antibody was first recognized as a marker of trophoblast cells 
and, it was developed looking for a marker for non-small-cell lung cancer (De Leij, Helrich, 
Stein, & Mattes, 1994), (Stein, Chen, Sharkey, & Goldenberg, 1990), (Stein, Basu, Chen, Shih, 
& Goldenberg, 1993). (Bardia, et al., 2021) reported that 88% of TNBC primary and metastatic 
tumors show moderate-to-strong expression of TROP-2. Recently, the FDA granted approval of 
Trodelvy (sacituzumab govitecan-hziy) a topoisomerase inhibitor conjugate directed to the 
TROP-2 receptor. This approval was based on the results of the ASCENT trial which was 
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conducted for the treatment of metastatic TNBC patients. This study showed that there was a 
significant difference in survival of TNBC patients treated with sacitizumab-14.2 months 
compared to chemotherapy treatment-6.9 months (Bardia, et al., 2021). 
 
I.4 The Metastatic Cascade 
The dissemination of TNBC cancer cells and metastatic growth to distal organs 
represents a significant health problem. The major secondary sites of metastatic TNBC are the 
lungs, liver, and brain (Chambers, Groom, & MacDonald, 2002), (Yao, et al., 2019). The 
metastatic disease is incurable and is the primary cause of death for the majority of TNBC 
patients. Metastatic spread of tumor cells consists of multiple steps, including local tumor cell 
invasion, entry into the vasculature, the exit of carcinoma cells from the circulation, formation of 
micrometastases followed by colonization at the distal sites. One of the earliest mentions of 
metastases postulated by (Paget, 1989) employing his “seed and soil” theory, proposed that 
secondary growth of cancer cells (the “seed”) is dependent on the compatibility of the distal 
organ (the “soil”). Currently, this theory has been supported as distinct cancer types metastasize 
at different and tumor-specific sites (Mack, et al., 2004), (Nguyen, Bos, & Massagué, 2009). 
In this process, cancer cells, after leaving the primary tumor, invade other tissues either 
by moving collectively as epithelial sheets, detached clusters, or as single cells (Friedl & 
Alexander, 2011).Upon genetic or epigenetic alterations, the TNBC cells at the primary tumor 
acquire anti-apoptotic properties such as self-renewal, invasion, and migration abilities to distal 
organs. Cancer stem cells are known for their self-renewal and chemoresistance capability, and it 
has been shown that TNBC is enriched in cancer stem cells (Honeth, et al., 2008), (Li, et al., 
2013). (Ricardo, et al., 2011) analyzed numerous human breast cancers and evaluated that 
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TNBCs harbor the highest percentage of CD44+/CD24- cancer stem cells, a feature that 
correlates with metastasis and overall poor survival. Additionally, specific growth factors and 
cytokines that activate several stemness pathways have been identified as essential drivers of 
TNBC proliferation and stemness (Marotta, et al., 2011). 
During local invasion, the cancer cells undergo epithelial-to-mesenchymal transition 
(EMT). The crucial steps of tumor metastasis are thought to be enabled by EMT (Ballinger, 
Kremer, & Miller, 2016), (Griffiths & Olin, 2012). Cells that have undergone EMT lose their 
epithelial organization and can become more motile and less invasive to move as single cells in a 
mesenchymal fashion (Mani, et al., 2008), (Thiery, 2002). Transcription factors activate EMT to 
promote TNBC cell migration and intravasation in the vasculature (Tran, et al., 2014), (Yang, et 
al., 2004). EMT is also associated with cancer stem cell properties, and as mentioned, TNBC 
expresses high CD44+/CD24− and EMT markers which is associated with poor survival 
outcome (Ma, et al., 2014), (Talukdar, et al., 2019), (Wicha, Liu, & Dontu, 2006). 
Upon entering the blood vessels, circulating tumor cells express proteins that have pro-
survival functions which allow them to attach and infiltrate specific secondary sites. In addition, 
the binding of platelets with circulating breast cancer cells are essential for their survival and 
evasion of pro-apoptotic signals (Neophytou, Boutsikos, & Papageorgis, 2018). (Wenzel, Zeisig, 
& Fichtner, 2010) evaluated that the disruption of platelet-tumor cell interaction inhibited the 
development of lung metastasis in TNBC murine model. Disseminated cells that survive pro-
apoptotic signals in their new environment undergo a dormancy period (Giancotti, 2013). 
After extravasation and the escape of the TNBC cells from the dormancy period, genetic 
modifications occur, and the cancer cells can form micro and macro-metastatic tumors at the 
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secondary sites (De Craene & Berx, 2013)In this step, the reversal to mesenchymal-to-epithelial 
transition (MET) phenotype have been shown to be important for metastatic colonization 
(Gunasinghe, Wells, Thompson, & Hugo, 2010). MET is characterized by epithelial 
reorganization and in this process, the mesenchymal cells regain the epithelial cell-to-cell 
junctions for colonization at distal sites (Kalluri & Weinberg, 2009), (Thiery, Acloque, Huang, & 
Nieto, 2009). 
It is important to understand the insights into the aggressiveness of TNBC by verifying 
the interactions between TNBC, CSC and EMT phenotypes. Therefore, understanding these 
phenotypes may be promising for exploring the development of novel effective treatments 
against metastasis of TNBC.  
 
I.5 Triple Negative Breast Cancer Liver Metastasis 
Triple Negative Breast Cancer metastases are common in organs such as the liver, brain, 
and lungs  (Liedtke, Mazouni, Hess, André, & Pusztai, 2008), (Hess, et al., 2006). BCLM are 
present in 15% of patients newly diagnosed with metastatic breast cancer and ultimately 50% of 
patients with stage four of the disease will develop liver metastases. When BCLM is left 
untreated, patient survival time is only 4 to 8 months with a very rare 5-year survival. Therefore, 
early prognosis and detection of liver metastasis is necessary to improve the life expectancy of 
TNBC patients (Adam, et al., 2006), (Hoe, Royle, & Taylor, 1991), (O'Reilly, Richards, & 
Rubens, 1990) (Selzner, Morse, Vredenburgh, Meyers, & Clavien, 2000). Patients with BCLM 
exhibit a wide array of symptoms, which may present asymptomatically during a metastatic 
screen or may present with upper abdominal fullness, a mass, ascites, jaundice, or weight loss 
(O'Reilly, Richards, & Rubens, 1990). Typically, an ultrasound or computed tomography (CT) 
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scan confirms the diagnosis. However, there have been two case studies in which asymptomatic 
presentation has been shown. Women of Asian and European American descent both conferred 
with TNBC via an abdominal CT scan, presented with liver metastases  (Chue & La Course, 
2019), (Ogata, et al., 2015). 
The molecular mechanisms underlying breast cancer metastasis have been especially 
reported for the lungs and bone (Chiu, et al., 2013), (Gao, et al., 2012), (Jiang, et al., 2012), 
(Minn, et al., 2005), (Suva, Griffin, & Makhoul, 2009), (Zhang, et al., 2013); however, the 
molecular mechanisms for BCLM have not been as thoroughly described (Lu, et al., 2007). 
(Parks & Garden, 2001) reported that the biological structure of the liver also makes it highly 
advantageous. The beneficial features are the abundant blood supply, the fenestrated blood 
vessels, and the lack of a sub-endothelial basement membrane. This allows for the movement 
and progression of the breast cancer cells within the liver microenvironment (Ma, et al., 2015). 
BCLM is associated with a few characteristics that result in the successful colonization of 
the secondary organ. These qualities include stem cell properties and proliferation signaling 
(Hess, et al., 2006), (Homayounfar, et al., 2013). Also, the breast carcinoma cells that secrete 
cytokines, chemokine receptors, cadherins promote cell adhesion to the endothelium, and 
integrin complexes which promote breast cancer cells to metastasize to the liver (Ma, et al., 
2015), (Wendel, et al., 2012). 
 
I.6 Triple Negative Breast Cancer Liver Metastasis Therapies 
A further understanding of the roles of TNBC cells and the liver microenvironment in 
early breast cancer metastasis is crucial for the development of effective BCLM therapies (Paget, 
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1989), (Price, Polyzos, Zhang, & Daniels, 1990). Current treatments for TNBC are systemic 
chemotherapy and radiation as the first-line treatment for cancer that has metastasized (Davis, 
Eckhardt, Tentler, & Diamond, 2014), (Cardoso, et al., 2018), (Hortobagyi, et al., 2005), 
(Schmid, et al., 2018), (Senkus, et al., 2015). However, even with these treatments patients 
ultimately become resistant to palliative therapy and have a poor response to chemotherapy 
which results in increased mortality in BCLM patients (Yao, et al., 2017). 
Raised serum alkaline phosphatase (ALP) has been established in patients with metastatic 
colorectal cancer but has not yet been evaluated as a diagnostic tool in BCLM. However, there 
have been small studies suggesting that elevated ALP, though not specific to liver metastasis is 
still useful in aiding the detection of the liver metastatic disease (Kamby, et al., 1987), (Klompje, 
Petrelli, Herrera, & Mittelman, 1987), (Warnes, Hine, Kay, & Smith, 1981). (Saif, Alexander, & 
Wicox, 2005) reported that patients with increased ALP levels were 5.5 times more likely to 
develop liver metastasis that patients with normal ALP levels. Thus, monitoring ALP levels at 
each patient’s follow-up can be used as an indicator since having liver metastasis is a good guide 
of disease progression. ALP is a simple, cost-conscious, and sensitive screening tool for 
detecting liver metastasis and can be developed in future studies of TNBC liver metastasis as a 
diagnostic tool.  
In several countries, such as Japan and Europe, other approved treatment options such as 
combined bevacizumab/paclitaxel/carboplatin (BCP) have been used for BCLM. BCP therapy 
has been used in the treatment of non-small cell lung cancers and significant improvements in 
survival rates have been reported (Sandler, et al., 2006). Additionally, (Ogata, et al., 2015) 
showed the successful treatment of BCP therapy in metastatic TNBC. Most importantly, the 
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patient has been in complete remission without additional treatment and has remained disease-
free after 5 years. Thus, this treatment has shown future promise for metastatic TNBC. 
Alternatively,  (Chue & La Course, 2019) demonstrated the use of metronomic 
chemotherapy as a viable TNBC liver metastasis treatment option. Metronomic chemotherapy 
uses lower doses of chemotherapy agents with higher dose intensity (the total dose of 
chemotherapy administered per unit time) while switching chemotherapy regimens every few 
weeks. This prevents the development of disease resistance and a better chance of achieving 
long-term survival (Greaves & Maley, 2012). However, drug resistance is still seen as the 
primary cause of failure of chemotherapy treatment for metastatic cancer and continuing a 
chemotherapy regimen until disease progression will inevitably increase the likelihood of a 
chemotherapy-resistant disease.  
More accumulated evidence suggested that the metastatic TNBC subtype can be 
particularly responsive to immunotherapy (García-Teijido, Cabal, Fernández, & Pérez, 2016). 
(Schmid, et al., 2018) study showed that treatment with atezolizumab–nab-paclitaxel benefitted 
patients with the programmed cell death-1 (PD-1) signal pathway which has a ligand called PD-
L1 that leads to apoptosis of malignant cells for TNBC (González-Cao, et al., 2015), (Pardoll, 
2012), (Wimberly, et al., 2015). The presence of PD-L1 may be a result of genetic events leading 
to constitutive PD-L1 expression on cancer cells versus non-cancer cells in response to a T cell 
infiltration. Thus, it is important to determine the PD-L1 expression status on tumor-infiltrating 
immune cells since it can be used as a treatment choice for patients with metastatic TNBC. 
Currently, Ipilimumab, pembrolizumab (anti-PD-1), and atezolizumab have been approved by 
the FDA in patients with overexpression of PD-L1 which helps in the therapeutics of TNBC 
patients with metastatic cancer (Narayan, et al., 2020). Furthermore, two new PD-L1 inhibitors 
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mepolizumab and nivolumab have been tested in current clinical trials. Unfortunately, 76% of 
TNBC patients having PD-L1 expression have not shown therapeutic response under 
mepolizumab therapy (Gibson, Delaune, Szady, & Markham, 2016).  
TNBC metastatic cancers can escape an antitumor immune response through the 
upregulation of regulatory T cells, secretion of immunosuppressive cytokines into the tumor 
microenvironment, as well as the expression of immunosuppressive proteins (Bohling & Allison, 
2008), (Drake, Jaffee, & Pardoll, 2006), (García-Teijido, Cabal, Fernández, & Pérez, 2016), 
(Smyth, Godfrey, & Trapani, 2001). Unfortunately, this situation is further exacerbated by the 
immunosuppressive effect of standard-dose chemotherapy (Kang, et al., 2009). Thus, the 
recruitment of the regulatory molecules to the tumor site may disarm the T-cell effectors and 
therefore favor the immunosuppressive activity of the tumor. As a result, this outweighs the 
body's antitumor immune response and consequently promotes tumor progression (Rabinovich, 
Gabrilovich, & Sotomayor, 2007). 
Moreover, a less arduous and more favorable treatment for TNBM liver metastasis is 
percutaneous ablation where doctors can utilize heat or cold to burn or freeze the tumor through 
a puncture thereby killing it. Using this method, high doses of ultrasound therapy can be applied 
to kill the tumor. Medical doctors also reported the establishment of a regional therapy technique 
when the tumors are multiple or diffuse. This therapy is chemoembolization, which means 
inserting a catheter that goes directly into the liver’s arteries to deliver very high levels of 
specialized toxic drugs precisely to the tumor (Yale Medicine, 2021) 
Methionine dependence is linked to epigenetic changes in cancer controlled by 
methylation events and is demonstrated as a promising target of metastatic TNBC (Hoffman, 
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2015). Cancer cells require increased levels of methionine (MET- dependence) due to the higher 
overall rates of transmethylation in comparison to normal cells (Coalson, Mecham, Stern, & 
Hoffman, 1982). (Kaiser, 2020) described the necessity of the cancer cells to have high 
methionine, is known as the Hoffman effect, analogous to the Warburg effect which describes 
the glucose overuse of cancer cells. In current research studies, recombinant methionase (o-
rMETase) inhibited the growth of the metastasis of cancer cells in vitro and in vivo (Hoffman, 
2015), (Lim, et al., 2020). These results suggest that o-rMETase has the potential as a new 
effective modality for metastatic TNBC, especially since it can be administered orally without 
toxicity (Han, Tan, & Hoffman, 2020), (Kawaguchi, et al., 2019). 
 
I.7 Angiopoietin-like protein 4 background and structure  
The angiopoietin-like protein 4 (ANGPTL4) was discovered approximately two decades 
ago and belongs to the angiopoietins family of secreted proteins which plays a role in the 
formation blood vessels. The eight members of angiopoietins are identified in humans and mice, 
except ANGPTL5, which is only found in humans (Ito, et al., 2003), (Kim, et al., 2000), 
(Santulli, 2014). All angiopoietin-like proteins have a C-terminal fibrinogen-like domain and an 
N-terminal coiled-coil domain. 
ANGPTL1 to 4 and ANGPTL6 have been shown to regulate angiogenesis. ANGPTL3 to 
6 and 8 are involved in the regulation of lipid metabolism, glucose and energy homeostasis 
(Koliwad, Gray, & Wang, 2012), (Oike, et al., 2005), (Xu, et al., 2005). (Lee, et al., 2009) 
evaluated that ANGPTLs 3 and 4 control lipid metabolism by inhibiting the activity of 
lipoprotein lipase, an enzyme that is responsible for the hydrolysis of triglycerides. ANGPTL4 is 
primarily present in the liver, adipose tissue, and skeletal muscle (Dijk, et al., 2015), (Kersten, et 
al., 2009), (Oike, et al., 2005), (Tan, Teo, Sng, Zhu, & Tan, 2012). 
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ANGPTL4 is evolutionarily conserved among species and the sequence is closely 
homologous with mice. It is located on chromosome 19p13.3 and comprised of seven exons with 
a 406-amino acid glycoprotein.  ANGPTL4 contains a hydrophobic region that acts as a signal 
peptide for protein secretion and exhibits several N- and O-glycosylation sites (Grootaert, Van de 
Wiele, Verstraete, Bracke, & Vanhoecke, 2012). Different studies showed that the nANGPTL4 
domain is used to modulate lipid metabolism, whereas the cANGPTL4 domain may be a 
modulator of the tumorigenesis process (Tan, Teo, Sng, Zhu, & Tan, 2012). ANGPTL4 functions 
as a LPL inhibitor due to an protein synthesis process mediated by the N-terminal region 
responsible for its assembly into 3D protein structures. Experimental analyses showed that 
proprotein convertases like furin, proprotein convertase 5/6, and proprotein convertase 
subtilisin/Kexin type 3 catalyze the proteolytic processing of the human flANGPTL4 protein via 
a particular amino acid sequence, which causes the release of the N-terminal region and a C-
terminal portion (Lei, et al., 2011), (Yau, et al., 2009). As a result, the shortened form of 
ANGPTl4 is secreted from the liver, whereas the full-length form is released from adipose tissue. 
Since ANGPTL4 expression was found mainly in the liver and adipose tissue, it was classified as 
an adipokine and as such its involvement in lipid metabolism is well characterized. 
Subsequently, many studies showed ANGPTL4 plays a highly versatile role in angiogenesis, 
vascular permeability, tumorigenesis, lipid metabolism and inflammation. 
 
I.8 The Role of ANGPTL4 in TNBC 
I.8.1 ANGPTL4 and regulatory factors in human cancers 
 
Previous studies have demonstrated that ANGPTL4 is involved in cancer growth, 
progression, angiogenesis, metabolism, and metastasis (Galaup, et al., 2006), (Kim, et al., 2011), 
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(Padua, et al., 2008), (Tan, Teo, Sng, Zhu, & Tan, 2012), (Zhu, et al., 2011). In several cancer 
types, the diverse roles of ANGPTL4 remain controversial and have reported involvement with 
many different signaling molecules and pathways. Several studies show that high levels of 
ANGPTL4 are associated with poor prognosis in patients with various solid tumors. This 
suggests that ANGPTL4 gives the cells the ability to acquire sustained proliferation, evading 
growth suppressors, resist apoptosis, replicative immortality, angiogenesis, invasion, and 
metastasis (Hanahan & Weinberg, 2011).  
Several studies have reported that the transcription factor hypoxia-inducible factor-1α 
(HIF-1α) stimulated by hypoxia can induce the upregulation of ANGPTL4 which stimulates 
angiogenesis (La Paglia, et al., 2017), (Kim, et al., 2011), (Li, et al., 2007), (Zhu, et al., 
2011).  Additionally, a previous study demonstrated that ANGPTL4 upregulation in endothelial 
cells plays a key role in the tumorigenesis of Kaposi’s sarcoma (Hu, et al., 2016). Furthermore, 
evidence suggests that ANGPTL4 acts via the transforming growth factor β (TGF-β) signaling 
pathway to promote tumor invasion and metastasis (Mathieu, et al., 2014). Moreover, ANGPTL4 
is the potential target gene for the three isoforms of peroxisome proliferator-activated receptor 
(PPAR) and PPARs have been implicated in the development of tumors in breast cancer cell 
lines (Girroir, et al., 2008), (Kim, et al., 2011). For other human cancers, studies reported that 
ANGPTL4 promotes invasion and metastasis as well (Dong, et al., 2017), (Hu, et al., 2016), 
(Nakayama, et al., 2011). 
These findings implicate ANGPTL4 in cancer progression, invasion, angiogenesis, and 
metastasis. More importantly, the research suggests that the expression and the role of 
ANGPTL4 in tumors are dependent on context and tumor type. This suggests the clinical 
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importance of ANGPTL4 in tumor biology and the research necessary to evaluate an effective 
targeted therapy against it. 
 
1.8.2 ANGPTL4 Primes Tumor Progression  
Increased ANGPTL4 expression has been shown to contribute enhanced tumor 
progression, metastasis, and poor overall survival. Conversely, studies have reported that the 
inhibition of ANGPTL4 reduces metastasis and tumorigenesis (Dao, et al., 2020), (Gong, et al., 
2019), (Kim, et al., 2011), (Padua, et al., 2008), (Zhao, et al., 2020), (Zhu, et al., 2011), (Wang, 
et al., 2013). As such it important to understand the role ANGPTL4 plays as a driver in tumor 
progression. 
In the (Gong, et al., 2019) study, the researchers evaluated the role of ANGPTL4 as 
promoter for TNBC brain metastasis in vivo and to further understand the interaction of the 
cancer cells with the astrocytes comprising of the human blood brain barrier in vitro. (Wang, et 
al., 2013) published that TNBC cells passaged in astrocyte cell medium enhanced brain trophism 
in a murine model. These observations suggested that the medium derived paracrine signaling of 
growth factors to promote seeding and metastasis of the brain. Thus, (Gong, et al., 2019) 
evaluated the role of ANGPTL4 expression in TNBC cells in astrocyte medium and found that it 
was induced by TGF-B and ANGPTL4 was significantly elevated suggesting their roles in tumor 
progression and metastasis. In the murine model, ANGPTL4 shRNA was expressed in the MDA-
MB-231 cell line and reduced the ability of the cancer cells to progress, seed and colonize the 
brain. As such (Gong, et al., 2019) reported ANGPTL4’s contribution to the metastatic lesions of 
MDA-MB-231 cells in the brain. 
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In another study, (Padua, et al., 2008) evaluated ANGPTL4’s function in TNBC 
colonization of the lung. The lung is one of the more common sites that TNBC cells can seed and 
metastasize. To investigate whether ANGPTL4 is involved in the metastatic colonization of the 
lungs, this research group inhibited the expression of ANGPTL4 in a TNBC cell line and 
orthotopically injected the TNBC cells in a murine model. They reported that the seeding to the 
lungs decreased more than 10-fold, suggesting that ANGPTL4 is involved in cancer cell’s ability 
to survive in circulation and seed to the lungs. In addition, they showed that the overexpression 
of ANGPTL4 in TNBC cells increased lung colonization by these cells. These results provide 
evidence that ANGPTL4 expression is necessary for the ability of TGFβ to prime the breast 
cancer cells for invasion of the lungs.  
Furthermore, (Padua, et al., 2008) investigated whether ANGPTL4 can affect the 
extravasation of the breast cancer cells through the endothelial tight junctions of the lung 
parenchyma. A lung permeability assay was performed in vivo with rhodamine signal. The 
TNBC cells expressing ANGPTL4 showed a 3-fold increase in the rhodamine signal, showing 
that ANGPTL4 can disrupt the integrity of the endothelial cell tight junctions and aid in 
colonization of the lungs. To further understand the role of ANGPTL4 in the TNBC migration 
through the cell-to-cell endothelial junctions an assay using tissue culture inserts. It was shown 
that TNBC cells overexpressing ANGPTL4 passed twice as much through the endothelial layers 
compared to control cells. This demonstrates that Angptl4 disrupts the integrity of vascular 
endothelial cell layers both in vitro and in the lungs, facilitating the passage of breast cancer cells 
(Bos, et al., 2009). Jointly, (Padua, et al., 2008) showed that of ANGPTL4 enhances TNBC cells 
migration, tumor progression, and extravasation to the lungs.  
23 
(Dao, et al., 2020) investigated the role of ANGPTL4 fragments in brain metastasis using 
a murine model. This group found that ANGPTL4 concentration in the serum is directly 
proportional to the increased risk of brain metastases and shorter survival in patients with breast 
cancer. Multivariate analyses performed by this research group showed that metastases were 
significantly associated with elevated ANGPTL4 concentration in the serum. In addition, they 
evaluated the proliferative, invasive, and migratory abilities of the breast cancer cells expressing 
nANGPTL4 and cANGPTL4 fragments. It was reported that tumor cells expressing the different 
fragments of ANGPTL4 had increased proliferation, migration and invasion compared to the 
wild type cells. For in vivo experiments, mice injected with cells expressing the fragment of 
nANGPTL4 had a shorter median survival of 19 days compared median time of 23 days for mice 
injected with wild-type cells. In addition, the mice injected with ANGPTL4 expressing cancer 
cells had significantly larger lung and brain metastasis compared to the mice injected with 
wildtype cells.  
(Zhao, et al., 2020) reported the association between ANGPTL4 expression and the 
different breast cancer tissues. They evaluated the expression levels of ANGPTL4 in different 
breast cancer tissue and shown that 63% of ANGPTL4 is expressed in IDCs, the highest 
percentage of ANGPTL4 expressed among all the breast cancer tissues. This means that as the 
malignancy of the tissues increased the rate of ANGPTL4 expression increased. Consequently, 
ANGPTL4 expression was associated with the worst prognosis in patients with IDC.  
Collectively, the in vivo and in vitro models in these studies of breast cancer have 
demonstrated the ability of ANGPTL4 to enhance tumor proliferation, migration, disruption of 
the endothelium cell-to-cell junction, invasion, and metastasis. 
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1.8.3 ANGPTL4’s Role in Anoikis Resistance 
 
Tumor cells abnormal growth suggests that anoikis should follow due to the stresses the 
cells are experiencing and, as a result cell growth progression should halt. However, 
proliferation, cell migration and metastasis continue to occur. This suggests that the cells are no 
longer reliant on the extracellular matrix for attachment and that the tumor cells have undergone 
anoikis resistance. Anoikis resistance is defined as the cells ability to evade cell death when there 
is loss of attachment to the extracellular matrix.  
(Zhu, et al., 2011) reported that enhanced ANGPTL4 expression promotes anoikis 
resistance to tumors via autocrine adhesion mimicry. It is noted that cANGPTL4 was detected 
and elevated in many human tumor cells (Hanahan & Weinberg, 2011).  
In their study, suppression of ANGPTL4 in the cancer cells formed 85% less colonies on 
a soft agar colony formation assay compared to the control cell line. In addition, in the anoikis 
assay the ANGPTL4 shRNA cell line was more susceptible to anoikis and resulted in 30% more 
apoptotic cells than the control cell line. 
The anoikis resistance effect of ANGPTL4 is mediated by reactive oxygen species 
(ROS). ANGPTL4 activates ROS which leads to an anti-apoptotic and anchorage-independent 
signals resulting in the tumor cells not being reliant on the extracellular matrix for normal 
growth. cANGPTL4 specifically binds to integrins βeta-1 and βeta-5 on tumor cells and activates 
pro-survival pathways, which further stimulates NADPH oxidase 1 activation via autocrine 
signaling (Zhu, et al., 2011). However, paracrine signaling can occur if the tissue expressing 
elevated cANGPTL4 is near the tumor (Desgrosellier & Cheresh, 2010). Downstream, this 
further triggers the inhibition of apoptotic proteins resulting in resistance to anoikis and favoring 
tumor survival and growth. 
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In a separate study, (Liao, et al., 2017) evaluate EGF-induced ANGPTL4 in tumour cells 
and anoikis resistance capability. The study showed that the secretion of EGF-induced 
ANGPTL4 was inhibited in ANGPTL4 shRNA cells which resulted in the reduction of EGF-
induced anoikis resistance. Conversely, the reduction of anoikis resistance could be reversed by 
treating the ANGPTL4 shRNA cells with recombinant cANGPTL4. Consequently, they 
evaluated that EGF-induced ANGPTL4 by autocrine signaling significantly enhanced anoikis 
resistance. Moreover, (Terada & Nwariaku, 2011) demonstrated that tumour derived ANGPTL4 
increases the production of ROS, resulting in activation of survival pathways to enhance anoikis 
resistance. 
 
1.8.4 ANGPTL4’s Role in Hypoxia and Angiogenesis 
Hypoxia induced by the overconsumption of oxygen by the rapidly growing tumor cells 
results in an oxygen deficit. This hypoxic environment triggers the onset of angiogenesis, which 
forms new blood vessels to supply oxygen, nutrients and remove metabolic waste products 
supporting tumor survival (Bertout, Patel, & Simon, 2008). It has been examined that 
angiogenesis is a multistep process that is regulated by vascular endothelial growth factors and 
ANGPTL4 (Le Jan, et al., 2003). Studies highlighted a prominent role for ANGPTL4 in tumor 
angiogenesis and vascular permeability. This increase in ANGPTL4 expression enhanced 
endothelial cell migration and differentiation, both of which are important processes in 
angiogenesis, resulting in increased neovascularization (Padua, et al., 2008). 
(Zhang, et al., 2012) identified that ANGPTL4 is a hypoxia-inducible factor 1 (HIF-1) 
target that contributes to vascular metastasis. HIF-1 is characterized as a transcription factor that 
occurs because of reduced oxygen availability and regulation of the genes that play roles in many 
factors of molecular biology like angiogenesis (Semenza, 2010). 
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(Le Jan, et al., 2003) indicated both the mRNA and protein ANGPTL4 levels become 
elevated because of hypoxia and, as a result exerts a proangiogenic effect. An elevated 
expression of ANGPTL4 was observed in breast cancer with the expression of cANGPTL4 
fragment highly correlated to the expression of HIF-1α (Zhang, et al., 2012). These observations 
indicate that ANGPTL4 could be a key modulator in tumor angiogenesis in a hypoxic tumor 
microenvironment.  
HIF-1 targets include numerous genes that play essential roles in promoting angiogenesis 
to increase oxygen delivery. Consequently, tumor cells metabolically shift from oxidative 
phosphorylation to glycolysis and lactic acid production to decrease oxygen demand. Thus, 
protecting cells from acidosis and influencing adaptive survival mechanisms (Semenza G. L., 
2012). Hypoxia is one of the most common and important factors identified in the regulation of 
cancer progression and metastasis (Kaelin, 2005), (Semenza G. L., 2012). 
 
I.9 TNBC and Tat-interactive protein p60 
Tat-interactive protein p60 (Tip60) is a member of the histone acetyltransferases and is 
directly involved in genome maintenance, gene regulation, and DNA damage repair pathways. 
Tip60 is the acetyltransferase component of a multiprotein complex that includes 16 subunits and 
contains an ATPase, p400 which can sensitize cells to death, and helicases-Tip49a and Tip49b 
(Fuchs, et al., 2001), (Samuelson, et al., 2005). The Tip60 complex preferentially acetylates 
histone binding acetylation targets H2AK5, H3K14, and H4K5/8/12/16 (Kimura & Horikoshi, 
1998). As a result of DNA damage, Tip60 is induced and then acetylates kinase activity at the 
sites of the damage (Legube, et al., 2002), (Sun, Jiang, & Price, 2010). Moreover, (Halkidou, et 
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al., 2003) reported that Tip60 predominantly accumulates in the nucleus of the tumor cell than a 
more diffused pattern which was observed in a benign state of prostate cancer.  
Tip60 roles are not only limited to DNA repair but also in apoptosis. Researchers have 
evaluated the relationship between Tip60 and cancer, which showed that Tip60 functions as a 
tumor suppressor (Gorrini, et al., 2007), (Squatrito, Gorrini, & Amati, 2006). In human cancers, 
Tip60 mRNA or protein level was downregulated and associated with poor prognosis in these 
patients (Chevillard-Briet, et al., 2014), (Gorrini, et al., 2007), (Mattera, et al., 2009), (Zhao, Jin, 
& Gewirtz, 2012).  It is also reported that in TNBC there are low expressions of TIP60 protein 
and RNA compared with luminal subtypes. (Idrissou, et al., 2020) reported successful inhibition 
of TIP60 activity in a TNBC cell line with chemical inhibitors. Studies on histone modifications 
in the appearance and progression mechanisms in TNBC would be essential in understanding the 
performances of TIP60 tumor biology (Stacy, et al., 2019). 
Although the effect of histone alterations has not been fully understood, histone modification 
inhibitors such as histone deacetylase inhibitors have emerged as a promising class of 
multifunctional anticancer agents to potentially prevent TNBC growth and metastasis (Fedele, 
Orlando, & Cinieri, 2017). These inhibitors could also help to better understand the effect of 
histone modifications on the outcome and the metastasis of TNBC through gene expression 
regulation to define new biomarkers and targeted therapies (Fedele, Orlando, & Cinieri, 2017), 
(Tate, et al., 2012). Tip60 was chosen for this study because it is suggested to be an interactor or 
in the pathway with ANGPTL4 as such it would be interesting to identify and understand its role 
in TNBC overexpressing ANGPTL4 cells. Studying this protein could potentially be used to 
further understand if ANGPTL4 and TIP60 are working together to affect the tumorigenic ability 
of the TNBC cells. 
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I.10 TNBC and Aurora Kinase A 
Abnormalities in genes controlling the cell cycle causes atypical cell proliferation, 
apoptosis, and transformation of malignant cells (Golias, Charalabopoulos, & Charalabopoulos, 
2004), (Williams & Stoeber, 2012). Aurora kinases (AURKA) are a family of mitotic 
serine/threonine kinases involved in different processes of cell cycle regulation and are 
associated with several co-activators that drive localization and activation during cell division 
(Barr & Gergely, 2007), (Fu, Bian, Jiang, & Zhang, 2007), (Vader & Lens, 2008). AURKA is 
overexpressed in many types of human cancers, notably in the different subtypes of breast 
cancers (Dar, Belkhiri, & El-Rifai, 2009), (Sen, et al., 2002), (Tanaka, et al., 1999). This 
overexpression correlates with tumorigenesis and metastasis confirming the survival function of 
AURKA in cancer cells. AURKA overexpression may occur by gene amplification, transcription 
activation, or suppression of protein degradation. Multiple studies evaluated different cancers 
and, showed that AURKA transcription may be induced by HIF-1α (Klein, Flügel, & Kietzmann, 
2008), (Lehman, et al., 2012). 
However, the molecular and transcriptional regulation mechanisms of AURKA remain 
unknown, especially in TNBC. (Fanale, et al., 2013) reported that hypoxia directly links HIF-1 
with AURKA expression in hormone-positive and HER2 overexpressing breast cancer cell lines 
and to a lesser extent TNBC. This highlights a possible pathophysiological role of this pathway 
in tumors and confirms that HIF-1 has an important role in signaling to the AURKA promoter. 
Since AURKA is a key regulator of the chromosomal segregation process in mammalian cells 
these results could provide innovative approaches for the development of possible therapeutic 
strategies against TNBC (Lee, et al., 2019). AURKA was chosen for this study because it is 
suggested to be an interactor with TIP60 or in the pathway with ANGPTL4. Therefore, it would 
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be noteworthy to identify its role in TNBC overexpressing ANGPTL4 cells. Studying this 
protein could potentially be used to further understand if its interaction with TIP60 and 
ANGPTL4 would be a driver for the tumor progression of the TNBC cells. 
 
1.11 Controversial Role of ANGPTL4 in Cancer 
ANGPTL4’s function remains debatable because of its multifaceted roles and, therefore 
further clarification is needed in tumorigenesis. However, several research groups have shown 
promising results suggesting that ANGPTL4 could be a potential therapeutic target in the battle 
against TNBC (Huang, et al., 2011), (Kim, et al., 2011), (Padua, et al., 2008), (Zhu, et al., 2011). 
It was reported that the immunosuppression of cANGPTL4 by neutralizing antibodies results in 
tumor regression, reduced vascular disruption, and metastasis (Huang, et al., 2011), (Zhu, et al., 
2011). Moreover, the inhibition of cANGPTL4 could potentially aid in chemosensitivity to 
cancer cells (Kim, et al., 2011). Given the implications that ANGPTL4 may have on cancer 
progression, a report suggested that ANGPTL4 mRNA could be used as a diagnostic marker to 
distinguish primary and metastatic cells in renal carcinoma (Verine, et al., 2010). A few other 
studies have also described ANGPTL4 expression level in primary and invasive tumors, that 
showed high ANGPTL4 mRNA and protein expression in human tumor biopsies often correlated 
with a poor prognosis and disease outcome (Hu, et al., 2016), (Kim, et al., 2011). (Zhu, et al., 
2011) and colleagues have shown that increased cANGPTL4 protein levels could be detected in 
the serum of tumor-bearing mice. cANGPTL4 was also found to be secreted by hypoxic cancer 
cells, lending further confidence to the potential use of ANGPTL4 as a biomarker (Kim, et al., 
2011). 
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Conversely, multiple studies reported that enhanced ANGPTL4 expression has inhibited 
tumor progression, invasion, and metastasis of tumor cells (Cazes, et al., 2006), (Galaup, et al., 
2006), (Ito, et al., 2003), (Le Jan, et al., 2003). Consequently, ANGPTL4 has been reported in 
promoting cancer cell’s tumorigenesis while also inhibiting tumor progression in different 
cancers (Ito, et al., 2003), (Le Jan, et al., 2003), (Ma, et al., 2015). Thus, ANGPTL4’s role in 
cancer progression needs to be further understood and more importantly its role in TNBC. 
 
1.12 Research Aims 
ANGPTL4 was shown to drive the invasion and metastatic capability of TNBC across the lung 
and brain parenchyma, this led to the central hypothesis that ANGPTL4 primes TNBC cells to 
disseminate and metastasize to the liver. ANGPTL4 is known as a secreted protein in the plasma 
membrane and serves a multifaceted role in cancer progression. Thus, the first aim of this study 
is to evaluate the role of intracellular ANGPTL4 in TNBC cells. Also, to investigate the 
localization and interaction of TIP60 and AURKA with ANGPTL4 experimentally. Since, TIP60 
and AURKA are predicted to be interactors in the ANGPTL4 pathway. The second aim is to 
assess the tumorigenic ability of exogenous ANGPTL4 in TNBC cells using a murine model.  
Research aim 1: The first aim was to assess the mechanism of intracellular ANGPTL4 in 
TNBC cells and examine the localization and compartmentalization of TIP60 and AURKA in the 
ANGPTL4 pathway in vitro.  
Research aim 2: The second aim was to evaluate the role of tumor-derived ANGPTL4 
overexpression in TNBC cells as a driver of metastases in vivo.  
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II. CHARACTERIZATION OF ANGPTL4 OVEREXPRESSION IN TNBC IN VITRO  
II.1 Introduction 
In this study the role of intracellular ANGPTL4 in TNBC cells and its ability to drive 
proliferation was evaluated. ANGPTL4 has been established as an enhancer of tumor 
progression in TNBC and a driver of lung, liver, and brain metastasis. Studies have reported that 
intracellular ANGPTL4 primes TNBC to extravasate and colonize the lung and brain 
parenchyma via TGF-B pathway (Gong, et al., 2019), (Padua, et al., 2008). In addition, 
ANGPTL4 promotes TNBC cells to escape anoikis. The breast cancer cells can grow in the 
absence of EMT attachment and with signaling from pro-survival proteins they gain anchorage 
independence where the cells continue to grow, migrate, and survive in the vasculature (Zhu, et 
al., 2011). In addition, TNBC is known to be enriched for stem cells, the CD44 high and CD24 
low phenotype, this means that the cancer stem cells have self-renewal, aggressive and increased 
metastatic ability (Idowu, et al., 2012), (Ricardo, et al., 2011). A study also reported that 
ANGPTL4 suppression inhibited the proliferation and migration of cancer cells in vitro, 
therefore solidifying its important in cancer progression (Huang, et al., 2011). Collectively, these 
studies indicate ANGPTL4 as a driver of metastatsis by enhancing tumor growth, cell motility 
and invasion (Tan, Teo, Sng, Zhu, & Tan, 2012). 
In this study, a lentiviral transduction was performed to overexpress ANGPTL4 in TNBC 
cell line and the overexpression was confirmed using confocal microscopy, ELISA and 
immunoblot analysis. The Human Protein Atlas predicted that ANGPTL4 is in the nucleoplasm 
and possibly in the vesicles, however the nuclear and chromatin localization of ANGPTL4 in 
TNBC has not been shown. In addition, TIP60 and AURKA are suggested to be interactors in the 
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ANGPTL4 pathway, as such ANGPTL4, TIP60 and AURKA localization were evaluated using 
immunofluorescence microscopy and western blot analysis. 
TNBC has the highest percentage of cancer stem cell population and is predicted to be 
more invasive and metastatic that the other breast cancer subtypes. To evaluate the ability of 
TNBC ANGPTL4 cells to form mammospheres and their ability to have an enriched stem cell 
population. A mammosphere assay was done with immunoblot analysis to confirm the stem cell 
phenotype by using CD44 and CD24 markers. 
In this study, Oil Red O staining was performed to evaluate the lipogenic profile of the 
TNBC cell line that overexpressing ANGPTL4 mammospheres. Furthermore, soft agar colony 
formation assay was done to assess anchorage independence in addition to cell colony growth 
and size in the TNBC ANGPTL4 cell line. 
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II.2 MATERIALS AND METHODS  
II.2.1 Cell Culture  
 
MD Anderson metastatic breast cancer 231 cells (MDA-MB-231), a TNBC cell line was 
cultured in Delbucco’s Modified Eagle Medium Nutrient Mixture F-12 (DMEM/F12 HAM) 
containing 5% fetal bovine serum (FBS), and 10 μg/ml gentamicin (complete medium) under 5% 
CO2 at 37°C. The MDA-MB-231 cells that overexpress mGFP tagged ANGPTL4 and mGFP 
only were cultured in Delbucco’s Modified Eagle Medium Nutrient Mixture F-12 (HAM) 
containing 5% FBS, 10 μg/ml gentamicin and 2 μg/ml puromycin at 37 °C under 5% CO2. 
 
II.2.2 Lentiviral mediated ANGPTL4 overexpression 
 
The MDA-MB-231 cell line was purchased from Sigma-Aldrich and, the lentiviral 
particles for the transduction was obtained from Origene. 1x105 MDA-MB-231 were seeded in a 
24 well plate and incubated for 24 hours. Then, the cells were transduced with the respective 
plasmids for 16 hours with 8 ug/ml of polybrene. Then, the virus-containing medium was 
removed and replaced with fresh complete medium. Selection with puromycin at 2 μg/ml was 
initiated 24 hours after transduction and continued for two weeks.  Single cells were propagated 
for three weeks. Colonies with robust GFP expression was determined by fluorescence 
microscopy and fluorescence activated cell sorting (FACS) were used in all subsequent 
experiments.  
 
II.2.3 Subcellular Protein Extraction 
 
Using MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cell lines, they were 
lysed, and cell fractions were isolated. This was done using a Subcellular Protein Fractionation 
kit (Thermo Fisher Scientific) for cultured cells according to the manufacturer’s guidelines. 
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II.2.4 Western Blotting 
 
ANGPTL4 overexpression in the MDA-MB-231 cell line was confirmed with SDS-Page 
and immunoblot analysis with an ANGPTL4 antibody(). MDA-MB-231 mGFP and ANGPTL4 
mGFP cells were rinsed twice with ice-cold PBS and attached cells were lysed in ice-cold Pierce 
Immunoprecipitation buffer containing Halt™ protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. The lysates were 
transferred to pre-cooled eppendorf tubes and spun at 13,000xg for 10 minutes at 4 °C. The 
supernatants were quantified for protein concentration and 25ug of protein lysates were resolved 
by gel electrophoresis and subjected to immunoblot analysis with antibodies specific for the 
indicated protein. 
 
II.2.5 Enzyme Linked Immunosorbent Assay 
MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were seeded in 
100mm x 20mm plates for 24 hours. Then, the cells were rinsed three times with Phosphate 
Buffered Saline (PBS) and grown in phenol red-free FBS in DMEM/F12 medium containing 
0.02% of gentamicin for 48 hours. The amount of secreted ANGPLT4 in cell culture medium of 
the respective cell lines were determined using a sandwich human ANGPTL4 ELISA kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions.  
 
II.2.6 Confocal Immunofluorescence Microscopy 
MDA-MB-231 mGFP and ANGPTL4 mGFP cells were seeded at a density of 75,000 
cells per well on glass coverslips inside a 24 well plate and grown for 48 hours. For GFP 
expression the cells were fixed at room temperature with 4% Paraformaldehyde (PFA) in the 
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dark, rinsed thrice with ice cold PBS and mounted with SlowFade™ Diamond Antifade 
Mountant with DAPI (InvitrogenTM). 
To stain for intracellular proteins, PFA was removed, and the cells on the coverslips were 
permeabilized for 10 minutes in immunofluorescence (IF) buffer consisting of 2% BSA/PBS 
with 0.2% saponin. The cells were rinsed in 2% BSA/PBS, incubated with primary antibodies 
overnight. Next day the coverslips were incubated with secondary antibodies for 1 hour at room 
temperature and rinsed three times (5 min each) in 2% BSA/PBS after each antibody incubation 
(Bailey, et al., 2014).The coverslips were rinsed once with PBS and mounted on glass 
microscope slides with SlowFade™ Diamond Antifade Mountant with DAPI 
(InvitrogenTM). 
All images were captured with a Leica confocal microscope and merged fluorescence pictures 
were generated using Fiji-ImageJ. 
 
II.2.7 Mammosphere Assay 
 
The MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were cultured for 
7 days in Mammocult medium (STEMCELLTM Technologies) at 37 °C under 5% CO2 on ultra-
low attachment plates or flasks. The colonies were counted and imaged with an inverted light 
microscope after 7 days. The mammospheres were used for immunoblotting and Oil Red O 
staining. The p-value was calculated using student’s t test using graph pad software, USA. 
 
II.2.8 Soft Agar Colony Formation Assay 
 
1.25 x 103 MDA-MB-231 mGFP or ANGPTL4 mGFP cells were suspended in complete 
medium with added 2ug/ml puromycin mixed with 3% noble agarose. The cells were seeded on 
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the semisolid layer of complete medium and 0.6% noble agarose in six well plates at 37 °C under 
5% CO2. Complete medium supplemented with 2ug/ml puromycin was added twice a week to 
prevent drying-out of the agarose and to preserve moisture. The colonies were counted and 
imaged using an inverted light Nikon Ti2 microscope after 7 days. The p-value was calculated 
using student’s t test using graph pad software, USA. 
 
II.2.9 Oil Red O staining 
 
Mammospheres were stained with Oil Red O stain (60% 0.5% Oil Red O Solution in 
40% ddH20) according to the manufacturer’s instructions. Fluorescent and brightfield 
mammosphere colonies were counted and photographed with an inverted light microscope after 





II.3.1 Generation and evaluation of ANGPTL4 expression in TNBC ANGPTL4 mGFP 
overexpression cell line. MDA-MB-231 cells were transduced with either the plasmid containing 
the empty vector or with the pLenti-C-mGFP-P2A-Puro plasmid with the ANGPTL4 gene. 
ANGPTL4 mGFP was designated as the MDA-MB-231 ANGPTL4 overexpression cell line and 
MDA-MB-231 overexpression empty vector control cell line referenced as MDA-MB-231 mGFP 
(Figure 2.1A).  Confocal microscopy showed the expression of mGFP expression in the control 
and ANGPTL4 mGFP cell lines were used with DAPI to determine staining of the nucleus (Figure 
2.1B). The genetically engineered cell lines mGFP and ANGPTL4 mGFP cells with strong 
homogenous mGFP expression was determined by fluorescence microscopy and FACs was then 
used for later experiments (Simeon J. (2017) Honors Thesis). 
Western blot analysis of ANGPTL4 expression in MDA-MB-231 overexpression cell lines.  Total 
protein was extracted from the cell lines and immunoblotted with antibodies. This result confirmed 
the expression of ANGPTL4 in the ANGPLT4 mGFP cell line and the lack of expression in the 
MDA-MB-231 cell line transduced with an empty vector (Figure 2.1C, Lane 2).  
ELISA Quantification of ANGPTL4 secretion by the transduced MDA-MB-231 overexpression 
cell lines. The amount of ANGPTL4 secreted in culture medium by MDA-MB-231 overexpression 
empty vector control and ANGPTL4 overexpression cell lines was assessed by an ELISA assay. 
As shown in Figure 2.1D, the MDA-MB-231 ANGPTL4 overexpression cell line secreted 
0.87735 ng/ml of ANGPLT4 in comparison to the MDA-MB-231 overexpression empty vector 
control cell line secreting 0.022 ng/ml, n=3. This confirmed ANGPTL4 overexpression in the 





















Figure 2.1: Lentiviral-mediated transduction of MDA-MD-231 overexpressing ANGPTL4 
confirmation. Map of lentiviral overexpression cloning vector, pLenti-C-mGFP-P2A-Puro 
plasmid (A). Confocal images of the cell lines expressing mGFP in the cells mounted on 
coverslips with DAPI for nuclear staining(B). Western blot analysis of ANGPTL4 expression 
with a commercially available ANGPTL4 antibody and GAPDH as the loading control(C). The 
amount of ANGPTL4 secreted by the cells measured by the ELISA kit (D) confirming that the 
ANGPTL4 mGFP cell line is overexpressing ANGPTL4. 
*Note: The lentiviral overexpression map image was adapted from Origene and reprinted from 
Honors Thesis (Simeon, 2017).The Characterization of Angiopoietin-like 4 dependent Triple 
Negative Breast Cancer Cells Extravasation using an in vitro model of the Human Blood Brain 
Barrier. Honors College, Fulbright College, University of Arkansas. 
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4 is 
a chromatin-bound protein that enhances mammosphere formation in vitro and experimental 
triple-negative breast cancer brain and liver metastases in vivo, 2021). Journal of 















































































II.3.2 The nuclear localization of chromatin bound ANGPTL4 and its association to Tip60 
and AURKA 
Subcellular fractions were accessed for intracellular localization of ANGPTL4 in TNBC 
cells. ANGPTL4 is predicted to be in the nucleoplasm and potentially in the vesicles as seen in 
the Human Protein Atlas database. So, to determine the intracellular localization of ANGPTL4 in 
the MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells, subcellular fractionation 
and intracellular staining were done. Subsequently, the cells from the respective cell lines were 
imaged with confocal immunofluorescence microscopy. The nuclear localization of ANGPTL4 
was confirmed (Fig 2.2A). TIP60 and AURKA are suggested to be interactors in the ANGPTL4 
pathway as such, intracellular staining was conducted to evaluate the localization of TIP60 and 
AURKA. TIP60 and AURKA was shown to colocalize in the nucleus of the MDA-MB-231 
ANGPTL4 cell line and not in the MDA-MB-231 mGFP cell line (Fig. 2.2A). ANGPTL4 being 
identified as a nuclear protein, was assessed in the chromatin lysate by immunoblot analysis to 
see if it also localizes in the chromatin. ANGPTL4 was present in the chromatin lysate of the 
MDA-MB-231 ANGPTL4 mGFP cell line and thus ANGPTL4 can be identified as a chromatin 
bound protein (Fig 2.2B). Tip60 and AURKA was also evaluated by immunoblot analysis to see 
if they were localized in the chromatin fractions. TIP 60 and AURKA was shown to localized in 
the chromatin of the MDA-MB-231 ANGPTL4 mGFP cells (Fig 2.3B). 















Figure 2.2: Chromatin bound ANGPTL4, TIP60 and AURKA. Immunoflourscense microscopy 
images of nuclear ANGPTL4, Tip60 and AURKA(A). Immunoblots depicting the presence of 
TIP60, AURKA and ANGPTL4 in chromatin fractions(B). 
*Note: This figure was reprinted from Simeon J, Thrush J, Bailey TA. (Simeon, Thrush, & 
Bailey, Angiopoietin-like protein 4 is a chromatin-bound protein that enhances mammosphere 
formation in vitro and experimental triple-negative breast cancer brain and liver metastases in 


























































































II.3.3 MDA-MB-231 overexpressing ANGPTL4 cells promotes increased stem cell 
formation 
 
The MDA-MB-231 mGFP and ANGPTL4 mGFP cell lines were evaluated for stem cell 
formation in mammocult media for 7 days. The number and the size of mammospheres 
quantified were analysed with brightfield and flourscence microscopy. The number of MDA-
MB-231 ANGPTL4 mGFP mammospheres were significantly greater than the mGFP 
mammospheres. The average number of mGFP and ANGPTL4 mGFP mammospheres that is ≥ 
200 µm is 0.75 um and 4.0 um, N=16 respectively. The quantity of mammospheres formed by 
the ANGPTL4 mGFP is 63, while the mGFP cell line had 12, N=3. The error bars depict 
standard deviation (Fig 2.3A). In terms of morphology, MDA-MB-231 mGFP cells formed small 
compacted aggregrates compared to the larger loosely compacted aggregrates formed by the 
MDA-MB-231 ANGPTL4 mGFP cells(Fig. 2.3B). Immunoblot analysis was done to evaluate 
the presence of the CD44 and CD24 markers in the adherent and stem cell population of MDA-
MB-231 mGFP and ANGPTL4 mGFP cell lines. Mammospheres derived from the mGFP and 
ANGPTL4 mGFP cell lines expressed smaller amounts of the CD24 marker compared to the 
adherent cell lines. CD44 marker being expressed by both the adherent and mammospheres 
mGFP and ANGPTL4 mGFP cell lines(Fig 2.3C). Oil Red O staining was used to analyze the 
presence of triglycerides in the mGFP and the ANGPTL4 mGFP cell lines. The ANGPTL4 
overexpressing cell lines retained more Oil Red O staining than the cell line expressing 
endogenous levels of ANGPTL4 suggesting that there is more triglycerides in the ANGPTL4 
mGFP cell line (Figure 2.3D). 
                             























Figure 2.3: The formation of mammospheres in vitro from MDA-MB-231 mGFP and 
ANGPTL4 mGFP cell lines. Graph showing the number of mammospheres ≥200 µm formed 
from mGFP and ANGPTL4 mGFP cells lines, respectively (A). Brightfield images of primary 
mammospheres formed in mammocult suspension resulting from the mGFP cell line and the 
ANGPTL4 mGFP cell lines (B). Western blot analysis was performed to evaluate for the 

























































p value =0.05 
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Figure 2.3: (Continued) derived from MDA-MB-231 mGFP and ANGPTL4 mGFP cells (C). 
Mammospheres formed from mGFP and ANGPTL4 mGFP cells stained with Oil Red O to 
analyze the presence of triglycerides(D). 
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4 
is a chromatin-bound protein that enhances mammosphere formation in vitro and experimental 







II.3.4 Angiopoietin like protein 4 promotes anchorage independent growth 
 
MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP cells were grown in media 
containing 0.3% agarose to produce a semi-solid medium. The ANGPTL4 overexpression cell 
line propagated more colonies than the mGFP cell line (Figure 2.4A). The average number of 
colonies ≥200 um derived from the MDA-MB-231 mGFP and ANGPTL4 mGFP cells were 11 
and 54 respectively, N=3. The combined average number of mGFP and ANGPTL4 mGFP 
colonies ≥200um was 0.305, N=36 and 5, N=36 repectively. Error bars depict standard error. In 
addition, brightfield and fluorescence microscopy shows that ANGPTL4 cells formed larger 
loosely aggregated cells like the morphology of the MDA-MB-231 ANGPTL4 mGFP 




                      
                 
 
 










Figure 2.4: MDA-MB-231 mGFP and ANGPTL4 mGFP cells showed anchorage independent 
growth. The  number(A) and morphology (B) of colonies formed from mGFP and ANGPTL4 
mGFP cells in 0.3% of agarose contaning medium shown using microscopy. 
*Note: This figure was reprinted from (Simeon, Thrush, & Bailey, Angiopoietin-like protein 4 is 
a chromatin-bound protein that enhances mammosphere formation in vitro and experimental 










































































To validate the role of intracellular ANGPTL4 expression in TNBC cell line, 
immunofluorescence microscopy, immunoblot analysis, mammosphere and soft agar colony 
formation assay can be used to determine the tumorigenic, anchorage-independence and invasive 
ability of the ANGPTL4 primed MDA-MB-231 cell line. ANGPTL4 overexpression was 
assessed and confirmed using immunoblot analysis, fluorescent microscopy, and an ELISA assay 
for use in the following experiments.  
Subcellular Fractionation, immunofluorescence microscopy and immunoblot analysis 
were performed to evaluate the localization of ANGPTL4, TIP60 and AURKA. According to the 
Human Atlas Protein database ANGPTL4 is predicted to be localized in the nucleosome and 
possibly the vesicles, however the localization of ANGPTL4 has yet to be shown in TNBC cells. 
ANGPTL4 was shown to localize in the nucleus and chromatin of MDA-MB-231 ANGPTL4 
mGFP cells. This means that ANGPTL4 is a chromatin bound protein and could potentially 
associate with DNA machinery in the chromatin. In addition, TIP60 and AURKA are possible 
interactors in the ANGPTL4 pathway as such their localization was evaluated as well. TIP60 and 
AURKA colocalized with ANGPTL4 in the nucleus and they were also present in the chromatin 
of the ANGPTL4 overexpressing cells.  
(McGuire, et al., 2019) evaluated that low Tip60 expression increases the risk of breast 
cancer reccurrence. In this study, TIP60 enhances of the tumorigenic capability of ANGPTL4 
mGFP cells due to the increased levels in ANGPTL4 overexpressing cell line.  Tip60 is a known 
to be involved in DNA damage response and transcriptional regulation (Gao, et al., 2014), (van 
Beekum, et al., 2008), (Sapountzi, Logan, & Robson, 2006). Tip60 is necessary for DNA repair 
via acetylation of the histones. In addition, Tip60 interacts with PARR, and it induces the 
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regulation of PPAR gamma activity, which stimulates lipid metabolism which aids in cancer 
progression (La Paglia, et al., 2017), (Li, et al., 2007), (van Beekum, et al., 2008). Therefore, 
ANGPTL4 and tip60 may be working together to alter the transcriptional regulation of genes 
associated with lipid metabolism or aid in DNA repair. 
In this study, a mammosphere assay was performed to determine the ability of ANGPTL4 
mGFP cells to form stem-cell enriched mammospheres. The mammospheres derived from the 
ANGPTL4 mGFP cells were significantly greater in the size and number compared to the 
mammospheres derived from the mGFP cell line. Additionally, immunoblot analysis showed that 
the mammospheres consisted of low levels of the CD24 and proportionate levels of the CD44 
stem cell markers compared to the adherent mGFP and ANGPTL4 mGFP cell lines. TNBC is 
enriched with cancer stem cells compared to other breast cancer subtypes and shows CD44 high 
and CD24 low phenotypes with self-renewal ability, enhances invasion and metastatic abilities 
(Ma, et al., 2014), (Honeth, et al., 2008). 
Oil Red O staining analyzed the presence of tricycerides in the mammospheres derived 
from the mGFP and ANGPTLL4 mGFP cells. The ANGPTL4 mGFP had increased staining 
intensity compared to the mGFP mammosphere cell line suggesting that there are elevated lipids 
in the ANGPTL4 mGFP mammosphere derived cells. Obesity is a risk factor for breast cancer 
and under obese conditions ANGPTL4 as a driver of cancer progression (Dietze, Chavez, & 
Seewaldt, 2018), (Kolb, et al., 2019), (Sun, et al., 2017). A study reported that patients with an 
upregulation of ANGPTL4 in uveal melanoma derived multicellular spheroids endured a 
metabolic shift to suggesting that ANGPTL4 could potentially play a role in lipid metabolism 
(Ness, et al., 2017). 
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Anchorage independent growth of the mGFP and the ANGPTL4 mGFP cell lines were 
evaluated using a soft agar colony formation assay. The ANGPTL4 mGFP cell lines propagated 
larger and a greater number of colonies compared to the mGFP cell line. This suggests that 
ANGPTL4 promotes anchorage independent growth of TNBC cells. (Zhu, et al., 2011) reported 
that ANGPTL4 drives anchorage-independence and as a result promotes the ability of cancer 













Cancer stems cells are known to make tumors more aggressive through self-renewal, 
migration, and therapy resistance. The MDA-MB-231 ANGPTL4 mGFP cell line had an 
increased number and growth of mammospheres formed in comparison to the mGFP cell line. 
Also, the morphology of the mammospheres between the two cell lines were different. The 
ANGPTL4 mGFP cells had bigger aggregates compared to the mGFP cell line. Therefore, that 
data suggests that ANGPTL4 is a driver of mammosphere formation in the MDA-MB-231 cell 
line. ANGPTL4 enhanced the anchorage independent growth of the MDA-MB-231 cell lines 
compared to the mGFP cell line. The ANGPTL4 mGFP cells showed increased colony growth 
and size similar to the mammospheres formed. 
In addition, the results suggested that ANGPTL4 is localized in the nucleus of TNBC 
cells and a chromatin bound protein. TIP60 and AURKA predictive interactors in the ANGPTL4 
pathway were localized in the nucleus and chromatin of the ANGPTL4 cell line.  TNBC cell line 
overexpressing ANGPTL4 was shown to retain more of the Oil Red O staining than the mGFP 
cell line expressing normal levels of ANGPTL4. This indicated that ANGPTL4 could potentially 
alter the lipid profile of the cells. DNA damage consists of alterations in chromatin structure and 
TIP60 is a chromatin-modifying protein and key component of repair. It also plays an important 
role in antiproliferative responses to DNA damage and elicits such control via acetylation of 
histones in the of DNA repair occurs. Additionally, TIP60 has a fundamental role in lipogenesis, 
and proper modulation might be a promising strategy for the alleviation of cancer related obesity 
and its associated metabolic diseases (Li, et al., 2018).  
As stated, aberrant expression of AURKA may lead to genetic instability and cause 
development of many cancers.  It’s role in promoting tumor progression, such as the activation 
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of epithelial–mesenchymal transition reprograms cancer cells stemness. Therefore, AURKA 
could be a potential attractive target for cancer therapeutics in conjuncture with breast cancer 
ANGPTL4 stemness phenotype. In conclusion, ANGPTL4 promotes tumor growth, formation of 
large cellular colonies and tumor stemness of TNBC cells in vitro. 
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III. ANGPTL4 ENHANCES TUMOR GROWTH AND LIVER METASTASES IN VIVO 
 III.1 Introduction 
 
After evaluating the role ANGPTL4 using in vitro assays, the overexpression of 
ANGPTL4 in TNBC was evaluated via in vivo studies. Scientists have used in vivo models as 
important research tools to study cancer initiation, invasion, and metastasis in a physiologically 
relevant system in breast cancer research. This represents an essential step between in 
vitro systems and clinical studies.  In vitro studies may not account for all the interactions 
between cells and biochemical processes that occur in the complexity of organ systems and thus 
the use of animals in in vivo studies addresses many of the disadvantages of only using in 
vitro studies (Tang, n.d.). In vivo studies also provide data that is important for validation of the 
function or proof of concept and for evaluation of efficacy of a gene or drug in a complex model 
(Vandamme, 2014). Moreover, advances in gene editing have helped scientists replicate human 
diseases in animals with better accuracy (Lee, et al., 2020). 
TNBC risk of distant recurrence peaks between 1 to 3 years after surgery and the time from 
recurrence to death is 9 months, significantly shorter than other types of breast cancer. Triple 
Negative Breast Cancer is associated with a higher rate of liver metastasis and, TNBC liver 
metastasis is fatal to patients who have not undergone treatment, usually having 4-6 months of 
survival before death (Kennecke, et al., 2010). To date, there are not many breast cancer mouse 
models that are developed focused on the formation of liver metastases only. (Rikhi, et al., 2016) 
established a murine model of direct injection of TNBC MDA-MB-231 cell line in the frontal 
lobe of the liver, which the researchers were able to evaluate invasion and metastasis to the 
lungs. (Lim, et al., 2020) established a liver-metastasis model of injecting TNBC from a patient 
and implanting it on the liver lobe by doing a surgical hepatic incision, simulating liver 
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metastasis. Using this model, they found lymph-node metastasis following liver metastasis 
growth. In this study, a nude mice model was used to study liver metastasis. Nude mice are 
athymic, so it makes them accepting of foreign cells which makes them great for cancer research, 
understanding the mechanism of malignant tumors and testing potentially treatments 
(Wettersten, Ganti, & Weiss, 2014), (Ito, et al., 2002). 
ANGPTL4 is a factor that has been shown to aid in tumor progression, metastasis, and 
invasion in a few human cancers. For these in vivo studies, the TNBC cell lines with the 
endogenous and overexpression of ANGPTL4 were injected subcutaneously in athymic mice 
and, the result of tumor growth and metastases was evaluated after a four-to-six-week period. 
The primary tumors and major organs were harvested for further analysis. Tissue resection and 
staining was done to determine the presence of ANGPTL4 and TIP60, in addition to Oil Red O 






III.2 MATERIALS AND METHODS 
 
III.2.1 Mouse human tumor xenograft model 
 All animal work was done in accordance with a protocol approved by the Institutional Care and 
Animal Use Committee at the University of Arkansas. Immunocompromised female mice age 
matched at four weeks old were used for xenografting studies. The mice were kept at the Central 
Laboratory Animal Facilities (CLAF), where they acclimatized for one week prior the 
experiment. The athymic mice were subcutaneously injected in the right flank with either the 
MDA-MB-231 cell line or the ANGPTL4 mGFP cell line or PBS. The allotted number of mice 
were held in a cage of dimensions 11.5”x 7.5’x5’ and was monitored once a day for physical 
and/or neurological distress post injection until euthanasia. Tumor areas were measured every 
three days using an electric caliper and were quantitated with the formula length multiplied by 
the width (LXW). The mice were anesthetized four to six weeks post subcutaneous injection 
with the cells, with isoflurane mixed with compressed air/oxygen. Primary tumors and organs 
were harvested for tissue immunofluorescence imaging to identify GFP-positive tumors and 
metastatic lesions. Two separate studies were conducted in which eight animals were used per 
cell line in study one, and in study two six animals were used per cell line. 
 
III.2.2 Whole Tissue Immunofluorescence Microscopy  
Primary tumors and liver tissue was sectioned at 6.0 µm and stained for intracellular proteins. 
Slices were fixed with 4% PFA, then the tissue slices were permeabilized for 20 minutes in 
immunofluorescence (IF) buffer consisting of 2% BSA/PBS with 0.2% saponin. The tissue slices 
were rinsed in 2% BSA/PBS, incubated with primary antibodies overnight and secondary 
antibodies for 1 h at room temperature with three rinses (5 min each) in 2% BSA/PBS after each 
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antibody incubation. After, the tissue slices were then rinsed thrice with PBS and mounted with 
SlowFade™ Diamond Antifade Mountant with DAPI (InvitrogenTM). 
All images were captured with a Nikon epifluorescence microscope in conjunction with NIS 
Elements software to obtain fluorescent images at the indicated magnifications. Merged 
fluorescence pictures were generated using Fiji-ImageJ. 
 
III.2.3 Oil Red O staining  
Primary tumors and liver tissue were stained with Oil Red O stain (60% 0.5% Oil Red O 
Solution in 40% ddH20) according to the manufacturer’s instructions. Tumor and liver tissue 
images were captured using a Nikon epifluorescence microscope in conjunction with NIS 
Elements software to obtain brightfield and fluorescent images at the indicated magnifications. 








III.3 RESULTS  
III.3.1 ANGPTL4 drives primary tumor size and promotes TNBC metastasis to the liver 
 
 To evaluate tumorigenicity and the metastatic ability of MDA-MB-231 mGFP and 
MDA-MB-231 ANGPTL4 mGFP overexpressing cell lines TNBC cells were injected 
subcutaneously in the right flank of the athymic female mice for a 4 to 6-week period two 
separate studies. The first study was conducted to evaluate liver metastasis in a 4-week period. A 
second study was designed to evaluate if the results were reproducible. The mice were evaluated 
over a 6-week period. The mice injected with the ANGPTL4 mGFP cells showed a greater mean 
primary tumor size in comparison to the mice that were injected with mGFP cells. Photographs 
showing tumor growth 4 weeks post injection of mice injected with mGFP and ANGPTL4 
mGFP cells. In study 1, The mean primary tumor area derived from mGFP and ANGPTL4 
mGFP cells were 3.14 mm2 and 20.32 mm2 respectively (Figure 3.1 A and B). In study 2, the 
mean area of the primary tumor area derived from the mGFP and ANGPTL4 mGFP cells is 0 
mm2 and 26.06 mm2 respectively, N=6. There was no area calculated for the primary tumor 
formed from the injected mGFP cells because it was diminutive. (data not shown) (Figure 3.1 C 
and D).  
The weights of the mice injected with MDA-MB-231 mGFP and ANGPTL4 mGFP were 
analyzed, however, there was not any significant difference in between the two sets of mice in 
both studies conducted. The mean weight of the mice xenograft injected with mGFP cells and 
ANGPTL4 mGFP cells was 25 and 24 g respectively in study 1 (Figure 3.2A).  In study 2, the 
mean weight of the mice xenograft injected with mGFP cells and ANGPTL4 mGFP cells was 23 
g and 22 g respectively (Figure 3.2B). The brains, spleen, lung, kidneys, intestines, and livers of 
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all mice were evaluated for mGFP-positive metastatic lesions. The organs containing no 
metastases were not shown.  
A comparison of the livers showed that seven out of the eight mice injected with 
ANGPTL4 mGFP cell line developed liver metastases, compared to one out of the eight mice 
injected with the MDA-MB-231 mGFP cell line developing metastasis (Figure 3.2C and D). 
Additionally, there was no significant difference in the liver weights measured from the mice 
injected with the MDA-MB-231 mGFP and MDA-MB-231 ANGPTL4 mGFP (Figure 3.2E). 
The mean liver weight of the mice injected with the mGFP cells and the ANGPTL4 cells was 
1276.15 mg and 1227.4 mg respectively. No metastatic lesions in the spleen, brains, spleen, 


















Figure 3.1: ANGPTL4 promotes tumor proliferation in vivo. Primary tumors were removed 
from mice 4 weeks post subcutaneous injection with MDA-MB-231 mGFP and ANGPTL4 
mGFP cells. Primary tumor photographs (A) and the mean tumor area (LxW) (B). In study 2, the 
images of primary tumors were taken 4 weeks post subcutaneous injection with MDA-MB-231 
mGFP and ANGPTL4 mGFP cells. Photographs of mice with primary tumors (C) and the mean 
tumor area (LxW) (B) 
*Note: This figure was reprinted from Simeon J, Thrush J, Bailey TA. (In Press). 
Angiopoietin‑like protein 4 is a chromatin‑bound protein that enhances mammosphere formation 
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Figure 3.2: Metastatic liver trophism derived from MDA-MB-231 mGFP cells and ANGPTL4 
mGFP cells injected in a mouse xenograft. Mean weight of the mice collected before euthanasia 
in both studies (A and B). Micrographs showing the number of metastatic lesions on the livers of 
mice subcutaneously injected with MDA-MB-231 ANGPTL4 mGFP cells and the mGFP 
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Figure 3.2: (Continued) with mGFP cells and ANGPTL4 mGFP cells(D). Mean liver weight of 
the mice collected after euthanasia (E).*Note: This figure was reprinted from Simeon J, Thrush 
J, Bailey TA. (In Press). Angiopoietin‑like protein 4 is a chromatin‑bound protein that enhances 
mammosphere formation in vitro and experimental triple‑negative breast cancer brain and liver 




III.3.3 Immunofluorescence microscopy and Oil Red O Staining of tissue resected from the 
mGFP and ANGPTL4 mGFP injected mice 
GFP+ TNBC liver metastases were excised from liver tissue and assessed for the presence of 
nuclear ANGPTL4, Tip60 and AURKA. No AURKA was detected (data not shown). ANGPTL4 
was expressed in the nucleus of the liver tissue around the metastatic lesion and primary tumor, 
immunofluorescence staining was done with ANGPTL4 antibody and imaged with 
immunofluorescence microscopy. Experiments in vitro showed that ANGPTL4 colocalized with 
Tip60, therefore, immunofluorescence analysis was done to evaluate if TIP60 is associated with 
ANGPTL4 in the liver tissue and primary tumors. The slices were mounted with DAPI (nuclear 
stain), and images were taken with a Nikon epifluorescence wide-field microscope. TIP60 and 
ANGPTL4 was shown to compartmentalize in the nucleus in both tumor and liver tissue. 
(Figure 3.3A) 
Oil Red O staining of the primary tumor (xenografts) and liver tissue derived from the 
mGFP and ANGPTL4 mGFP cell line evaluated for the presence of triglycerides was 
comparable between the mice. The Oil Red O staining was proportional between the mGFP and 
ANGPTL4 mGFP Liver and tumor tissue. (Figure 3.4B) Tissue slices were stained with 60% 
0.5% Oil Red O Solution in 40% ddH20, counterstained with hematoxylin and imaged using a 

























Figure 3.5: Immunoflouresence microscopy showing the colocalization of ANGPTL4 and 
Tip60(A). Oil Red O staining of the primary tumors and liver tissue from the mice injected with 













































































































Figure 3.5:(Continued) Immunoflouresence microscopy showing the colocalization of 
ANGPTL4 and Tip60(A). Oil Red O staining of the primary tumors and liver tissue from the 




















































































III.6 Discussion  
 
The liver is a site of breast cancer metastasis, along with bone and lung (Berman, Thukral, 
Hwang, Solin, & Vapiwala, 2013), (Hess, et al., 2006). Liver metastasis in TNBC patients results 
in a poor prognosis (Bonotto, et al., 2014), (Gerratana, et al., 2015) and as median survival of 
breast cancer patients with liver metastasis ranges from 4-6 months if left untreated. Thus, a 
clinical need for a liver TNBC murine model is necessary to investigate the mechanisms used by 
metastatic tumor cells and what can be used as a potential therapeutic option. 
Currently, there a few mouse models to evaluate breast cancer liver metastasis with varying 
results that pose their own challenges. The intrasplenic injection delivers tumor cells via the 
splenic vein (Soares, et al., 2014). The intrasplenic injection minimizes the development of 
simultaneous multi-distal metastasis which allows for the study of specific liver metastases. 
However, the intrasplenic model requires the removal of the spleen splenic tumors, this 
procedure that impacts immune function.  
The most commonly used model of breast cancer metastasis relies on the intracardiac 
injection which occurs by injecting tumor cells directly into the circulation via the tail vein or left 
ventricle of the heart (Minn, et al., Genes that mediate breast cancer metastasis to lung, 2005), 
(Kang, et al., 2003). Injection of the tumor cells result in bone, brain, lung, and liver metastasis, 
including other organs (Basse, Hokland, Heron, & Hokland, 1988). Due to the multi distal organ 
metastases, these mice frequently need to be euthanized before evaluating specific liver 
metastasis preventing the ability to fully investigate metastatic growth within the liver.  
Orthotopic injections of include the injection of tumor cells in the mammary fat pad of 
immune competent hosts to assess subsequent metastasis (Aslakson & Miller, 1992), (Dexter, et 
al., 1978). But the rate of liver metastasis from using this model, like the subcutaneous injection 
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is very low compared to other metastatic sites such as the lung. The orthotopic and portal vein 
injection results in liver metastasis after lung metastasis is established, complicating the need of 
liver-specific metastasis (Aslakson & Miller, 1992), (Doornebal, et al., 2013). 
Another murine model for cancer liver metastasis utilizes spontaneous metastasis in 
genetically engineered mice. To date, reports of spontaneous murine models of breast cancer 
metastasis that readily spread to the liver are not common and if they do develop it is in a low 
percentage of mice (Derksen, et al., 2006), (Fantozzi & Christofori, 2006). 
The portal vein injection model was developed to address the need for improved liver 
metastasis models, that delivers tumor cells directly to the liver. This model delivers tumor cells 
to the liver without complications of concurrent metastases in other organs or removal of the 
spleen. Additionally, it represents an important tool to study breast cancer metastasis to the liver 
and may be applicable to other cancers that frequently metastasize to the liver including 
colorectal and pancreatic cancer.  
The subcutaneous model used for this study is known as a spontaneous model for 
metastasis. This model has its own advantages and disadvantages. A few strengths for using this 
model are the metastatic disease development from tumor, site mimics human disease 
progression and low cost. However, it’s only applicable to certain cell lines, asynchronous 
metastatic development occurs, and the mouse microenvironment (Gómez-Cuadrado, Tracey, 
Ma, Qian, & Brunton, 2017). (Munoz, et al., 2006) showed the subcutaneous model using MDA-
MB-231 cells usually metastasize to the liver, lung and lymph nodes. 
To validate the role of ANGPTL4 in TNBC in vivo, subcutaneous injection was 
conducted to determine tumorigenesis, invasiveness, and metastatic capability of ANGPTL4 
overexpressing TNBC cells.  
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ANGPTL4 drives tumor growth and TNBC liver metastasis. The MDA-MB-231 mGFP 
and ANGPTL4 mGFP cells were injected subcutaneously into the murine model and after a 4–6-
week period the primary tumors (xenografts) and livers were resected. The mice injected with 
the ANGPTL4 cell line had greater tumor area and number compared to the mGFP cell line. This 
showed that ANGPTL4 is a driver of proliferation of the TNBC cells. ANGPTL4 enhances 
proliferation of many human cancers including breast, bone, thyroid (Munoz, et al., 2006), 
(Yang, et al., 2020), (Zhang, et al., 2012). 
ANGPTL4 enhances liver metastasis of TNBC cells. Majority of the ANGPTL4 mice 
developed liver metastasis, whereas only one mouse developed liver metastasis when injected 
with mGFP cell line. ANGPTL4 is promotes cancer cell invasion and metastasis. ANGPTL4 has 
been shown to prime breast cancer cells to disrupts the endothelial cell to cell junction of the 
lung and brain parenchyma to invade and colonize these distal organs (Gong, et al., 2019), 
(Padua, et al., 2008). 
Additionally, TIP60 is localized with ANGPTL4 in the nucleus of the primary tumors 
(xenografts) and the liver tissue resected around the metastatic lesion in the ANGPTL4 mGFP 
mice. TIP60 regulates gene transcription and DNA damage response. Tip60 can also function in 
cancer cell progression and metastatic ability of the cancer cells because of the epithelial and 






ANGPTL4 serves an important role in tumor cell motility, invasion, cell migration and 
metastasis. It has also been reported to inhibit metastases in lung and gastric cancers by 
preventing tumor progression and invasiveness (Chen, et al., 2018), (Tan, Teo, Sng, Zhu, & Tan, 
2012). Conversely, ANGPTL4 expression seems to fluctuate in different human cancers such 
oral, hepatocellular, colorectal, and renal cancer. Therefore, since ANGPTL4 doesn’t appear to 
have a consistent role in its expression in tumors, there is currently no effective targeted therapy 
against ANGPTL4 or standard molecular mechanism in which it aids tumor progression and 
metastases in all human cancers. 
In this study, the role of ANGPTL4 is evaluated in TNBC. The findings from this study 
demonstrate that the overexpression of ANGPTL4 in TNBC cells is strongly associated with 
increase growth, primary tumor formation and metastatic liver trophism in vivo. 
Furthermore, the role of TIP60 and ANGPTL4 in the MDA-MB-231 cell line was also 
assessed. The epithelial to mesenchymal transition is controlled by epigenetic modifications such 
as histone acetylation. As mentioned, TIP60, a histone acetyltransferase that functions in DNA 
repair relates to these transitions in cancer progression to tumour dissemination and high relapse 
in breast cancer. Here, it is shown that ANGPTL4 is localized with TIP60 in the primary tumor 
(xenograft) and liver tissue resected from the mice derived from the ANGPTL4 overexpression 
cell line. 
In this study, it has been demonstrated that ANGPTL4 promotes tumor size and 






IV. FUTURE DIRECTIONS 
 
TNBC liver metastasis standard treatment is chemotherapy with a high chance of 
recurrence and increased incidences of death. Therefore, it is imperative to evaluate efficient 
treatment options that may lengthen and increase the quality of life of TNBC metastatic patients. 
One feasible area for favorable treatment strategy is exploiting the immune system to control 
metastatic cancer in TNBC. Tumor-associated antigens can be recognized by the immune system 
and evoke an immune response which may result in tumor cell death due to a T-cell tumor-
specific response (García-Teijido, Cabal, Fernández, & Pérez, Tumor-Infiltrating Lymphocytes 
in Triple Negative Breast Cancer: The Future of Immune Targeting, 2016). However, tumor cell 
variants can evade the immune system by the activation of immune suppressive pathway and 
escape immune destruction. As mentioned, TNBC is associated with high levels of tumor 
infiltrating leukocytes and PD-L1 expression, supporting the investigation of immune checkpoint 
inhibitors (Pelekanou, et al., 2018). As a result, developing new and precise molecular 
biomarkers during prognosis would help to differentiate TNBC metastatic tumors because of its 
heterogenous nature. Cancer biomarkers can monitor an individual’s risk of developing cancer in 
a specific tissue such as the liver and a result develop an efficient alternative for treatment.  In 
addition, morphological and functional imaging technologies can also be used during in vivo 
experiments which can track measurements of the metastatic biological processes. 
The mouse model in this study of that can be used to evaluate effective therapies for 
TNBC liver metastasis. This is important because patients with TNBC liver metastasis have poor 
prognosis, and a high mortality rate. One advantage is that this mouse model is athymic as such 
it expresses predominately macrophages. The dynamic function of macrophages was evaluated 
as M1 macrophages being tumoricidal, whereas M2 macrophages promotes cancer (Mills, 2012), 
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(Mills, Lenz, & Harris, A Breakthrough: Macrophage-Directed Cancer Immunotherapy, 2016). 
ANGPTL4 is significantly expressed in macrophages and has shown to drive the polarization of 
macrophages in colorectal cancer (Aryal, et al., 2016). Therefore, a future experiment would be 
to evaluate immunotherapies that causes M1 polarization in the tumor immune 
microenvironment of TNBC xenografts that overexpress ANGPTL4.  
The current chemotherapy therapeutic strategies for the management of TNBC are 
platinum compounds and taxanes targeting DNA repair complexes, taxanes for p53 and 
anthracycline regimen for cell proliferation. TNBC is very aggressive and heterogenous subtype 
of breast cancer. Though, TNBC responds well to chemotherapy, incidences of recurrence are 
very high, and prognosis remains poor. (Verma, Provencher, & Dent, 2011) reported a treatment 
review of TNBC patients undergoing treatment and evaluated that the first line for metastatic 
treatment would be the standard chemotherapy drugs despite the current development of novel 
targeted therapies.  
TNBC metastatic patients with visceral metastases have a relatively shorter overall 
survival have limited duration of response to successive lines of chemotherapy. So, it is 
imperative to select the agents most likely to result in a more meaningful treatment and possibly 
a longer overall survival. Therefore, because of TNBC biologically heterogenous nature, 
identifying molecular biomarkers to predict response to specific chemotherapy is requred to 
further improve treatment strategies with the current number of chemotherapy options and future 
combinations with targeted therapies so patients can have a better overall survival. 
 




Breast cancer now most common form of cancer: WHO taking action. (2021, February 3rd ). 
Retrieved from World Health Organization: https://www.who.int/news/item/03-02-2021-
breast-cancer-now-most-common-form-of-cancer-who-taking-action 
Molecular Subtypes of Breast Cancer. (2021, April 7). Retrieved from breast cancer.org: 
https://www.breastcancer.org/symptoms/types/molecular-subtypes 
Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., . . . 
W. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a 
relationship between subtype and short and long term survival: a collaborative analysis of 
data for 10,159 cases from 12 studies. Plos Medicine, e1000279. 
Dai, X. L., Bai, Z., Yang, Y., Liu, X., Zhan, J., & & Shi, B. (2015). Breast cancer intrinsic 
subtype classification, clinical use and future trends. American journal of cancer 
research, 2929–2943. 
Li, L. T., Jiang, G., Chen, Q., & Zheng, J. N. (2015). Ki67 is a promising molecular target in the 
diagnosis of cancer (review). Molecular medicine reports, 1566–1572. 
Sun, X., & Kaufman, P. D. (2018). Ki-67: more than a proliferation marker. Chromosoma, 175–
186. 
National Institute of Health. Surveillance, Epidemiology, and End Results Program . (2017). 
Retrieved from National Cancer Institute : https://seer.cancer.gov 
Keam, B., Im, S. A., Lee, K. H., Han, S. W., Oh, D. Y., Kim, J. H., . . . Bang, Y. J. (2011). Ki-67 
can be used for further classification of triple negative breast cancer into two subtypes 
with different response and prognosis. Breast Cancer Research , R22. 
Soliman, H., Khalil, F., & Antonia, S. (2014). PD-L1 expression is increased in a subset of basal 
type breast cancer cells. PLoS One, 14;9(2):e88557. 
Herr, D., Wischnewsky, M., Joukhadar, R., Chow, O., Janni, W., Leinert, E., . . . Wöckel, A. 
(2019). Does chemotherapy improve survival in patients with nodal positive luminal A 
breast cancer? A restropective Multicenter Study. Plos One, 14(7), e0218434. 
Boyle, P. (2012). Triple-negative breast cancer: epidemiological considerations and 
recommendations. Annals of oncology : official journal of the European Society for 
Medical Oncology, vi7–vi12. 
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. The New 
England journal of medicine, 1938–1948. 
Kumar, P., & Aggarwal, R. (2016). An overview of triple-negative breast cancer. Archives of 
Gynecology and Obstetrics, 247-269. 
70 
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., . . . Narod, S. A. 
(2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer 
patients. Breast cancer research and treatment, 359–363. 
Comen, E., Davids, M., Kirchhoff, T., Hudis, C., Offit, K., & Robson, M. (2011). Relative 
contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in 
Ashkenazi Women. . Breast cancer research and treatment, 185–190. 
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., . . . Narod, S. 
A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. . 
Clinical cancer research : an official journal of the American Association for Cancer 
Research, 4429–4434. 
Foulkes, W. D., Stefansson, I. M., Chappuis, P. O., Bégin, L. R., Goffin, J. R., Wong, N., . . . 
Akslen, L. A. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in 
breast cancer. . Journal of the National Cancer Institute, 1482–1485. 
Kirk, R. (2010). Breast cancer cells—escape artists. . Nat Rev Clin Oncol, 483. 
Lundqvist, A., Andersson, E., Ahlberg, I., Nilbert, M., & Gerdtham, U. (2016). Socioeconomic 
inequalities in breast cancer incidence and mortality in Europe-a systematic review and 
meta-analysis. European journal of public health, 804–813. 
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., . . . 
Terry, M. (2012). Pathology of breast and ovarian cancers among BRCA1 and BRCA2 
mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 
(CIMBA). Cancer epidemiology, biomarkers & prevention : a publication of the 
American Association for Cancer Research, cosponsored by the American Society of 
Preventive Oncology, 134–147. . 
Musolino, A., Bella, M. A., Bortesi, B., Michiara, M., Naldi, N., Zanelli, P., . . . Ardizzoni, A. 
(2007). BRCA mutations, molecular markers, and clinical variables in early-onset breast 
cancer: a population-based study. Breast (Edinburgh, Scotland), 280–292. 
Prat, A., & Perou, C. (2011). Deconstructing the molecular portraits of breast cancer. Molecular 
oncology, 5–23. 
Philipovskiy, A., Corral, J., Dwivedi, K. A., Heydarian, R., & Gaur, S. (2019). Efficacy of 
Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With 
Local or Locally Advanced Triple-negative Breast Cancer (TNBC). In vivo (Athens, 
Greece), 1227–1234. 
Turner, N., Tutt, A., & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. 
Nature reviews, 814-819. 
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive 
analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and 
71 
HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a 
population-based study from the California cancer Registry. Cancer, 1721–1728. 
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., . . . Millikan, 
R. C. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer 
Study. JAMA, 2492–2502. 
Jiagge, E., Jibril, A. S., Chitale, D., Bensenhaver, J. M., Awuah, B. H., Bekele, M., . . . Stark, A. 
(2016). Comparative Analysis of Breast Cancer Phenotypes in African American, White 
American, and West Versus East African patients: Correlation Between African Ancestry 
and Triple-Negative Breast Cancer. Annals of surgical oncology, 3843–3849. 
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., . . . 
Penberthy, L. (2015). Annual Report to the Nation on the Status of Cancer, 1975-2011, 
Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. 
Journal of the National Cancer Institute, djv048. 
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., . . . Børresen-Dale, A. 
L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses 
with clinical implications. Proceedings of the National Academy of Sciences of the 
United States of America, 10869–10874. 
Bonotto, M., Gerratana, L., Poletto, E., Driol, P., Giangreco, M., Russo, S., . . . Puglisi, F. 
(2014). Measures of outcome in metastatic breast cancer: insights from a real-world 
scenario. The oncologist, 608–615. 
Clark, S. L., Rodriguez, A. M., Snyder, R. R., Hankins, G. D., & Boehning, D. (2012). Structure-
Function Of The Tumor Suppressor BRCA1. Computational and structural 
biotechnology journal, e201204005. 
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., . . . 
Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: a cancer journal for clinicians, 
438–451. 
Hunter, C. (2000). Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in 
multiracial and multiethnic populations. Cancer. Cancer, 1193–1202. 
Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics. CA: a cancer journal for 
clinicians, 7–30. 
Stewart, R. L., Updike, K. L., Factor, R. E., Henry, N. L., Boucher, K. M., Bernard, P. S., & 
Varley, K. E. (2019). A Multigene Assay Determines Risk of Recurrence in Patients with 
Triple-Negative Breast Cancer. Cancer research, 3466–3478. 
Nanda, R., Schumm, L. P., Cummings, S., Fackenthal, J. D., Sveen, L., Ademuyiwa, F., . . . 
Olopade, O. I. (2005). Genetic testing in an ethnically diverse cohort of high-risk women: 
a comparative analysis of BRCA1 and BRCA2 mutations in American families of 
European and African ancestry. JAMA, 1925–1933. 
72 
Qian, J., Chen, H., Ji, X., Eisenberg, R., Chakravarthy, A. B., Mayer, I. A., & Massion, P. P. 
(2017). A 3q gene signature associated with triple negative breast cancer organ specific 
metastasis and response to neoadjuvant chemotherapy. Scientific reports, 45828. 
Szabo, C. I., & King, M. C. (1997). Population genetics of BRCA1 and BRCA2. . American 
journal of human genetics, 1013–1020. 
Santonja, A., Sánchez-Muñoz, A., Lluch, A., Chica-Parrado, M. R., Albanell, J., Chacón, J. I., & 
Antolín, S. J.-D.-T. (2018). Triple negative breast cancer subtypes and pathologic 
complete response rate to neoadjuvant chemotherapy. Oncotarget, 26406–26416. 
Kwon, J. S., Gutierrez-Barrera, A. M., Young, D., Sun, C. C., Daniels, M. S., Lu, K. H., & Arun, 
B. (2010). Expanding the criteria for BRCA mutation testing in breast cancer survivors. 
Journal of clinical oncology. official journal of the American Society of Clinical 
Oncology, 4214–4220. 
Hossain, F., Danos, D., Prakash, O., Gilliland, A., Ferguson, T. F., Simonsen, N., . . . Scribner, 
R. (2019). Neighborhood Social Determinants of Triple Negative Breast Cancer. 
Frontiers in public health, 7, 18. 
Lara-Medina, F. P.-S.-P.-C.-K.-G.-A. (2011). Triple-negative breast cancer in Hispanic patients: 
high prevalence, poor prognosis, and association with menopausal status, body mass 
index, and parity. . Cancer, 3658–3669. 
Patel, T. A., Colon-Otero, G., Bueno Hume, C., Copland, J. A., 3rd, & Perez, E. A. (2010). 
Breast cancer in Latinas: gene expression, differential response to treatments, and 
differential toxicities in Latinas compared with other population groups. . The oncologist, 
466–475. 
Siddharth, S., & Sharma, D. (2018). acial Disparity and Triple-Negative Breast Cancer in 
African-American Women: A Multifaceted Affair between Obesity, Biology, and 
Socioeconomic Determinants. Cancers, 514. 
Sturtz, L. A., Melley, J., Mamula, K., Shriver, C. D., & Ellsworth, R. E. (2014). Outcome 
disparities in African American women with triple negative breast cancer: a comparison 
of epidemiological and molecular factors between African American and Caucasian 
women with triple negative breast cancer. BMC cancer, 62. 
Elrafei, N. T., Prassana, D., Castaldi, M., Msaouel, P., Strakhan, M., Alexis, M. K., & Gralla, J. 
R. (2014). Medical and socioeconomic factors associated with triple-negative breast 
cancer (TNBC) in women with health care disparities. Journal of Clinical Oncology, 
e17512-e17512. 
Parise, C., & Caggiano, V. (2018). The influence of marital status and race/ethnicity on risk of 
mortality for triple negative breast cancer. PloS one, e0196134. 
73 
Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., . . . Prentice, R. 
(2005). Ethnicity and breast cancer: factors influencing differences in incidence and 
outcome. Journal of the National Cancer Institute, 439–448. 
Mack, K. P., Pavao, J., Tabnak, F., Knutson, K., & Kimerling, R. (2009). Adherence to recent 
screening mammography among Latinas: findings from the California Women's Health 
Survey. Journal of women's health, 347–354. 
Alsan, M. G., & Graziani, G. (2019). Does Diversity Matter for Health? Experimental Evidence 
from Oakland. American Economic Review, 4071-4111. 
Scharff, D. P., Mathews, K. J., Jackson, P., Hoffsuemmer, J., Martin, E., & Edwards, D. (2010). 
More than Tuskegee: understanding mistrust about research participation. Journal of 
health care for the poor and underserved. Journal of health care for the poor and 
underserved, 879–897. 
Shavers, V. L., & Brown, M. L. (2002). Racial and ethnic disparities in the receipt of cancer 
treatment. Journal of the National Cancer Institute, 334–357. 
US Preventive Services Task Force, O. D., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, 
M., Caughey, A. B., . . . Tseng, C. (2019). Risk Assessment, Genetic Counseling, and 
Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force 
Recommendation Statement. JAMA, 652–665. 
Collett, K., Stefansson, I. M., Eide, J., Braaten, A., Wang, H., Eide, G. E., . . . Akslen, L. A. 
(2005). A basal epithelial phenotype is more frequent in interval breast cancers compared 
with screen detected tumors. Cancer epidemiology, biomarkers & prevention : a 
publication of the American Association for Cancer Research, cosponsored by the 
American Society of Preventive Oncology, 1108–1112. 
Brown, S. A., Kunz, D., Dumas, A., Westermark, P. O., Vanselow, K., Tilmann-Wahnschaffe, 
A., . . . Kramer, A. (2008). Molecular insights into human daily behavior. Proceedings of 
the National Academy of Sciences of the United States of America,, 1602–1607. 
Vranic, S., Tawfik, O., Palazzo, J., Bilalovic, N., Eyzaguirre, E., Lee, L. M., . . . Gatalica, Z. 
(2010). EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. 
Modern pathology : an official journal of the United States and Canadian Academy of 
Pathology, 644–653. 
Yerushalmi, R., Hayes, M. M., & Gelmon, K. A. (2009). Breast carcinoma--rare types: review of 
the literature. Annals of oncology : official journal of the European Society for Medical 
Oncology, 1763–1770. 
Kleer, G. C. (2009). Carcinoma of the breast with medullary-like features: diagnostic challenges 
and relationship with BRCA1 and EZH2 functions. Archives of pathology & laboratory 
medicine, 1822–1825. 
74 
Lakhani, S., Ellis, I., Schnitt, S., Tan, P., & van de Vijver, M. (2012). WHO Classification of 
Tumours of the Breast. Lyon: IARC. 
Pedersen, L., Schiødt, T., Holck, S., & & Zedeler, K. (1990). The prognostic importance of 
syncytial growth pattern in medullary carcinoma of the breast. APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica, 921–926. 
Weigelt, B., Horlings, H. M., Kreike, B., Hayes, M. M., Hauptmann, M., Wessels, L. F., . . . 
Peterse, J. L. (2008). Refinement of breast cancer classification by molecular 
characterization of histological special types. The Journal of pathology, 141–150. 
Jung, K., Gupta, N., Wang, P., Lewis, J. T., Gopal, K., Wu, F., . . . Lai, R. (2015). riple negative 
breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high 
responsiveness to a Sox2 regulatory region 2 (SRR2) reporter. Oncotarget, 10366–10373. 
Criscitiello, C., Azim, H. A., Jr, S. P., Linn, S. C., & Sotiriou, C. (2012). Understanding the 
biology of triple-negative breast cancer. Annals of oncology : official journal of the 
European Society for Medical Oncology, vi13–vi18. 
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G., . . . Martens, J. W. (2008). 
Subtypes of breast cancer show preferential site of relapse. Cancer research, 3108–3114. 
Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The 
Journal of pathology, 275–292. 
Cinkaya, A., Akin, M., & Sengul, A. (2016). Evaluation of treatment outcomes of triple-negative 
breast cancer. Journal of cancer research and therapeutics, 150–154. 
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., . . . 
Pusztai, L. (2005). Breast cancer molecular subtypes respond differently to preoperative 
chemotherapy. Clinical cancer research : an official journal of the American Association 
for Cancer Research, 5678–5685. 
Geisler, S., Lønning, P. E., Aas, T., Johnsen, H., Fluge, O., Haugen, D. F., . . . Børresen-Dale, A. 
L. (2001). Influence of TP53 gene alterations and c-erbB-2 expression on the response to 
treatment with doxorubicin in locally advanced breast cancer. Cancer research, 2505–
2512. 
Liedtke, C., Mazouni, C., Hess, K. R., André, F. T.-A., & Pusztai, L. (2008). Response to 
neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 1275–1281. 
Petrelli, F., De Stefani, A., Raspagliesi, F., Lorusso, D., & Barni, S. (2014). Radiotherapy with 
concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic 
review and meta-analysis. Gynecologic oncology, 166–171. 
75 
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., . . . E. (2010). 
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of clinical 
oncology . official journal of the American Society of Clinical Oncology, 1145–1153. 
Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., McIntyre, K. J., . . . 
Hyman, W. J. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall 
Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-
Up of US Oncology Research Trial 9735. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology, 1177–1183. 
Schreiber, R. A., Kagihara, J., Eguchi, M., Kabos, P., Meyer, E., Kondapalli, L., . . . Diamond, J. 
( 2020). Adjuvant chemotherapy with or without an anthracycline in older adults with 
node-negative triple-negative breast cancer (TNBC): A SEER Medicare study. Journal of 
Clinical Oncology, e12505-e12505 . 
Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Di Bonito, M., D'Aiuto, M., . . . D'Aiuto, G. 
(2009). Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-
negative large operable breast cancer. Annals of oncology : official journal of the 
European Society for Medical Oncology, 1185–1192. 
Freedman, G. M., Anderson, P. R., Li, T., & Nicolaou, N. (2009). Locoregional recurrence of 
triple-negative breast cancer after breast-conserving surgery and radiation. Cancer, 946–
951. 
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010). Prognosis 
of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an 
institutional-based review. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology, 92–98. 
He, M. Y., Rancoule, C., Rehailia-Blanchard, A., Espenel, S., Trone, J. C., Bernichon, E., . . . 
Magné, N. (2018). Radiotherapy in triple-negative breast cancer: Current situation and 
upcoming strategies. Critical reviews in oncology/hematology, 96–101. 
Yin, L., Gao, Y., Zhang, X., Wang, J., Ding, D., Zhang, Y., . . . Chen, H. (2016). Niclosamide 
sensitizes triple-negative breast cancer cells to ionizing radiation in association with the 
inhibition of Wnt/β-catenin signaling. Oncotarget, 42126–42138. 
Kulbachinskiy, A. V. (2007). Methods for selection of aptamers to protein targets. Biochemistry. 
Biokhimiia, 1505–1518. 
Li, Z., Qiu, Y., Lu, W., Jiang, Y., & Wang, J. (2018). Immunotherapeutic interventions of Triple 
Negative Breast Cancer. Journal of translational medicine, 147. 
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012). Differential macrophage programming in 
the tumor microenvironment. Trends in immunology, 119–126. 
76 
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994). 
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to 
CD28 and CTLA-4 receptors. Immunity, 793–801. 
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., . . . Rosenberg, 
S. A. (2005). Tumor regression and autoimmunity in patients treated with cytotoxic T 
lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Annals of 
surgical oncology, 1005–1016. 
Friedberg, E. C., Aguilera, A., Gellert, M., Hanawalt, P. C., Hays, J. B., Lehmann, A. R., . . . 
Wood, R. D. (2006). DNA repair: from molecular mechanism to human disease. DNA 
repair, 986–996. 
Chen, Z., Yang, H., & Pavletich, N. P. (2008). Mechanism of homologous recombination from 
the RecA-ssDNA/dsDNA structures. Nature, 7194. 
Rothstein, R., Michel, B., & Gangloff, S. (2000). Replication fork pausing and recombination or 
"gimme a break". Genes & development, 1-10. 
Degrassi, F., Fiore, M., & Palitti, F. (2004). Chromosomal aberrations and genomic instability 
induced by topoisomerase-targeted antitumour drugs. Current medicinal chemistry, 317–
325. 
Shrivastav, M., De Haro, L. P., & Nickoloff, J. A. (2008). Regulation of DNA double-strand 
break repair pathway choice. Cell research, 134–147. 
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015). Homologous recombination and human 
health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harbor 
perspectives in biology, a016600. 
Sadeghi, M., Ordway, B., Rafiei, I., Borad, P., Fang, B., Koomen, J. L., . . . Damaghi, M. (2020). 
Integrative Analysis of Breast Cancer Cells Reveals an Epithelial-Mesenchymal 
Transition Role in Adaptation to Acidic Microenvironment. Frontiers in oncology, 304. 
Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016). Molecular Classification of Triple-Negative 
Breast Cancer. Journal of breast cancer, 223–230. 
Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., . . . Li, X. (2018). Association Between 
BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Frontiers in 
pharmacology, 909. 
Evans, D. G., Howell, A., Ward, D., Lalloo, F., Jones, J. L., & Eccles, D. M. (2011). Prevalence 
of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of medical 
genetics, 2011-100006. 
Greenup, R., Buchanan, A., Lorizio, W., Rhoads, K., Chan, S., Leedom, T., . . . Shelley Hwang, 
E. (2013). Prevalence of BRCA mutations among women with triple-negative breast 
cancer (TNBC) in a genetic counseling cohort. Annals of surgical oncology, 3254–3258. 
77 
Schreiber, V., Hunting, D., Trucco, C., Gowans, B., Grunwald, D., De Murcia, G., & De Murcia, 
J. M. (1995). A dominant-negative mutant of human poly(ADP-ribose) polymerase 
affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. 
roceedings of the National Academy of Sciences of the United States of America, 4753–
4757. 
Skidmore, C. J., Davies, M. I., Goodwin, P. M., Halldorsson, H., Lewis, P. J., Shall, S., & Zia'ee, 
A. A. (1979). The involvement of poly(ADP-ribose) polymerase in the degradation of 
NAD caused by gamma-radiation and N-methyl-N-nitrosourea. European journal of 
biochemistry, 135–142. 
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008). DNA repair 
pathways as targets for cancer therapy. Nature reviews, Cancer, 193–204. 
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., lsen, A., . . . Sherman, C. (2008). 
First in human phase 1 study of BSI-20, a small molecule inhibitor of poly ADP-ribose 
polymerase(PARP) in subjects with advance solid tumors. Journal of Clinical Oncology, 
3577-3577 . 
Kopetz, S., Mita, M., Mok, I., Sankhala, K., Moseley, J., Sherman, B., . . . Tolcher, A. (2008). 
First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose 
polymerase (PARP) in subjects with advanced solid tumors. Journal of Clinical 
Oncology, 3577-3577. 
Mahany, J. J., Lewis, H., Heath, E., LoRusso P.M, M. M., A.W, T., B.M., S., . . . K.P, P. (2008). 
A phase 1B study evaluating BS1-201 in combination with chemotherapy in subjects 
with advanced solid tumors. Journal of Clinical Oncology, 3579-3579. 
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009). Defective repair of oxidative 
dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-
ribose) polymerase. Cancer research, 3589–3596. 
Hastak, K., Alli, E., & Ford, J. M. (2010). Synergistic chemosensitivity of triple-negative breast 
cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. 
Cancer research, 7970–7980. 
Papadimitriou, M., Mountzios, G., & Papadimitriou, C. A. (2018). The role of PARP inhibition 
in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. 
Cancer treatment reviews, 34–44. 
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of 
metastatic spread in triple-negative breast cancer. Breast cancer research and treatment, 
423–428. 
Ward, J. (1988). DNA damage produced by ionizing radiation in mammalian cells: identities, 
mechanisms of formation, and reparability. Progress in nucleic acid research and 
molecular biology, 95–125. 
78 
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., . . . Ashworth, 
A. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 1111–
1115. 
Gelmon, K., H.W., H. H., Robidoux, A., Tonkin, K., Tischkowitz, M., & Swenerton, K. (2010). 
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study 
of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. Journal 
of Clinical Oncology, abstract 3002. 
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & 
Palacios, J. (2006). Prognostic significance of basal-like phenotype and fascin expression 
in node-negative invasive breast carcinomas. Clinical cancer research. an official journal 
of the American Association for Cancer Research, 1533–1539. 
Lipinski, M., Parks, D. R., Rouse, R. V., & Herzenberg, L. A. (1981). Human trophoblast cell-
surface antigens defined by monoclonal antibodies. Proceedings of the National Academy 
of Sciences of the United States of America, 5147–5150. 
De Leij, L., Helrich, W., Stein, R., & Mattes, M. J. (1994). SCLC-cluster-2 antibodies detect the 
pancarcinoma/epithelial glycoprotein EGP-2. International journal of cancer, 60–63. 
Stein, R., Chen, S., Sharkey, R. M., & Goldenberg, D. M. (1990). Murine monoclonal antibodies 
raised against human non-small cell carcinoma of the lung: specificity and tumor 
targeting. Cancer research, 1330–1336. 
Stein, R., Basu, A., Chen, S., Shih, L. B., & Goldenberg, D. M. (1993). Specificity and 
properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal 
antibody. International journal of cancer, 938–946. 
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., . . . Fe. (2021). 
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England 
journal of medicine, 1529–1541. 
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer 
cells in metastatic sites. Cancer, 563–572. 
Yao, B., Qu, S., Hu, R., Gao, W., Jin, S., Ju, J., & Zhao, Q. (2019). Delivery of platelet TPM3 
mRNA into breast cancer cells via microvesicles enhances metastasis. FEBS open bio, 
2159–2169. 
Paget, S. (1989). The distribution of secondary growths in cancer of the breast. Cancer 
metastasis reviews, 98–101. 
Mack, M. G., Straub, R., Eichler, K., Söllner, O., Lehnert, T., & Vogl, T. J. (2004). Breast cancer 
metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and 
survival data. Radiology, 400–409. 
79 
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009). Metastasis: from dissemination to organ-
specific colonization. Cancer, 274–284. 
Friedl, P., & Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and 
reciprocity. Cell, 992–1009. 
Honeth, G., Bendahl, P. O., Ringnér, M., Saal, L. H., Gruvberger-Saal, S. K., Lövgren, K., . . . 
Hegardt, C. (2008). The CD44+/CD24- phenotype is enriched in basal-like breast tumors. 
Breast cancer research : BCR, R53. 
Li, H., Ma, F., Wang, H., Lin, C., Fan, Y., Zhang, X., . . . Xu, B. (2013). Stem cell marker 
aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative 
breast cancer. The International journal of biological markers, e357–e364. 
Ricardo, S., Vieira, A. F., Gerhard, R., Leitão, D., Pinto, R., Cameselle-Teijeiro, J. F., . . . 
Paredes, J. (2011). Breast cancer stem cell markers CD44, CD24 and ALDH1: expression 
distribution within intrinsic molecular subtype. Journal of clinical pathology, 937–946. 
Marotta, L. L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., . . . Park, 
S. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ 
stem cell-like breast cancer cells in human tumors. The Journal of clinical investigation, 
2723–2735. 
Ballinger, T., Kremer, J., & Miller, K. (2016). Triple Negative Breast Cancer—Review of 
Current and Emerging Therapeutic Strategies. Oncology & Hematology Review, 89–94. 
Griffiths, C. L., & Olin, J. L. (2012). Triple negative breast cancer: a brief review of its 
characteristics and treatment options. Journal of pharmacy practice, 319–323. 
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., . . . Weinberg, R. A. 
(2008). The epithelial-mesenchymal transition generates cells with properties of stem 
cells. Cell, 704–715. 
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Cancer, 442–
454. 
Tran, H. D., Luitel, K., Kim, M., Zhang, K., Longmore, G. D., & Tran, D. D. (2014). Transient 
SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer 
research, 6330–6340. 
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., . . . Weinberg, 
R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor 
metastasis. . Cell, 927–939. 
Ma, F., Li, H., Wang, H., Shi, X., Fan, Y., Ding, X., . . . Xu, B. (2014). Enriched 
CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-
negative breast cancer (TNBC). Cancer letters, 153–159. 
80 
Talukdar, S., Bhoopathi, P., Emdad, L., Das, S., Sarkar, D., & Fisher, P. B. (2019). Dormancy 
and cancer stem cells: An enigma for cancer therapeutic targeting. Advances in cancer 
research, 43–84. 
Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea--a paradigm shift. 
Cancer research, 1883–1896. 
Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018). Molecular Mechanisms and Emerging 
Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. Frontiers in oncology, 
31. 
Wenzel, J., Zeisig, R., & Fichtner, I. (2010). Inhibition of metastasis in a murine 4T1 breast 
cancer model by liposomes preventing tumor cell-platelet interactions. Clinical & 
experimental metastasis, 25–34. 
Giancotti, F. G. (2013). Mechanisms governing metastatic dormancy and reactivation. Cell, 750–
764. 
De Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation 
and progression. Cancer, 97–110. 
Gunasinghe, N. P., Wells, A., Thompson, E. W., & Hugo, H. J. (2010). Mesenchymal-epithelial 
transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer 
metastasis reviews, 469–478. 
Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The 
Journal of clinical investigation, 1420–1428. 
Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal 
transitions in development and disease. Cell, 871–890. 
Hess, K. R., Varadhachary, G. R., Taylor, S. H., Wei, W., Raber, M. N., Lenzi, R., & 
Abbruzzese, J. L. (2006). Metastatic patterns in adenocarcinoma. Cancer, 1624–1633. 
Adam, R., Aloia, T., Krissat, J., Bralet, M. P., Paule, B., Giacchetti, S., . . . Castaing, D. (2006). 
Is liver resection justified for patients with hepatic metastases from breast cancer? Annals 
of surgery, 897–908. 
Hoe, A. L., Royle, G. T., & Taylor, I. (1991). Breast liver metastases--incidence, diagnosis and 
outcome. Journal of the Royal Society of Medicine, 714–716. 
O'Reilly, S. M., Richards, M. A., & Rubens, R. D. (1990). Liver metastases from breast cancer: 
the relationship between clinical, biochemical and pathological features and survival. 
European journal of cancer (Oxford, England : 1990), 574–577. 
Selzner, M., Morse, M. A., Vredenburgh, J. J., Meyers, W. C., & Clavien, P. A. (2000). Liver 
metastases from breast cancer: long-term survival after curative resection. Surgery, 383–
389. 
81 
Chue, B. M., & La Course, B. D. (2019). Case report of long-term survival with metastatic triple-
negative breast carcinoma: Treatment possibilities for metastatic disease. Medicine, 
e15302. 
Ogata, H., Kikuchi, Y., Natori, K., Shiraga, N., Kobayashi, M., Magoshi, S., . . . Kaneko, H. 
(2015). Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 
5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case 
Report and Review of the Literature. Medicine, e1756. 
Chiu, H. W., Yeh, Y. L., Wang, Y. C., Huang, W. J., Chen, Y. A., Chiou, Y. S., . . . Wang, Y. J. 
(2013). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances 
radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. 
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances 
radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo, 
e76340. . 
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mo, Q., Decker, M., Vonica, A., . . . Giancotti, F. G. 
(2012). The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. 
Cell, 764–779. 
Jiang, J., Thyagarajan-Sahu, A., Loganathan, J., Eliaz, I., Terry, C., Sandusky, G. E., & Sliva, D. 
(2012). BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic 
animal model of triple-negative human breast cancer. Oncology reports, Oncology 
reports. 
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., . . . Massagué, J. 
(2005). Genes that mediate breast cancer metastasis to lung. Nature, 518–524. 
Suva, L. J., Griffin, R. J., & Makhoul, I. (2009). Mechanisms of bone metastases of breast 
cancer. Endocrine-related cancer, 703–713. 
Zhang, X. H., Jin, X., Malladi, S., Zou, Y., Wen, Y. H., Brogi, E., . . . Massagué, J. (2013). 
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. 
Cell, 1060–1073. 
Lu, M. D., Jiang, T. A., Chen, M. H., Zhao, B. Z., Zhou, X. D., & Wang, J. R. (2007). 
Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in 
monitoring percutaneous thermal ablation procedure in patients with hepatocellular 
carcinoma: a multi-center study in China. Ultrasound in medicine & biology, 1736–1749. 
Parks, R. W., & Garden, O. J. (2001). Liver resection for cancer. World journal of 
gastroenterology, 766–771. 
Ma, R., Feng, Y., Lin, S., Chen, J., Lin, H., Liang, X., . . . Cai, X. (2015). Mechanisms involved 
in breast cancer liver metastasis. Journal of translational medicine, 64. 
Homayounfar, K., Bleckmann, A., Conradi, L. C., Sprenger, T., Lorf, T., Niessner, M., . . . 
Ghadimi, B. M. (2013). Metastatic recurrence after complete resection of colorectal liver 
82 
metastases: impact of surgery and chemotherapy on survival. International journal of 
colorectal disease, 1009–1017. 
Wendel, C., Hemping-Bovenkerk, A., Krasnyanska, J., Mees, S. T., Kochetkova, M., Stoeppeler, 
S., & Haier, J. (2012). CXCR4/CXCL12 participate in extravasation of metastasizing 
breast cancer cells within the liver in a rat model. PloS one, e30046. 
Price, J. E., Polyzos, A., Zhang, R. D., & Daniels, L. M. (1990). Tumorigenicity and metastasis 
of human breast carcinoma cell lines in nude mice. Cancer research, 717–721. 
Davis, S. L., Eckhardt, S. G., Tentler, J. J., & Diamond, J. R. (2014). Triple-negative breast 
cancer: bridging the gap from cancer genomics to predictive biomarkers. Therapeutic 
advances in medical oncology, 88–100. 
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., . . . Mayer, 
M. (2018). Global analysis of advanced/metastatic breast cancer: Decade report (2005-
2015). Breast (Edinburgh, Scotland), 131–138. 
Hortobagyi, G. N., de la Garza Salazar, J., Pritchard, K., Amadori, D., Haidinger, R., Hudis, C. 
A., . . . Investigators, A. (2005). The global breast cancer burden: variations in 
epidemiology and survival. Clinical breast cancer, 391–401. 
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., . . . Inv, I. T. 
(2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. 
The New England journal of medicine, 2108–2121. 
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., . . . 
Committee, E. G. (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Annals of oncology : official journal of the European 
Society for Medical Oncology, v8–v30. 
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2017). Triple-negative 
breast cancer: is there a treatment on the horizon? Oncotarget, 1913–1924. 
Kamby, C., Dirksen, H., Vejborg, I., Daugaard, S., Guldhammer, B., Rossing, N., & Mouridsen, 
H. T. (1987). Incidence and methodologic aspects of the occurrence of liver metastases in 
recurrent breast cancer. Cancer, 1524–1529. 
Klompje, J., Petrelli, N. J., Herrera, L., & Mittelman, A. (1987). The prognostic value of 
preoperative alkaline phosphatase for resection of solitary liver metastasis from colorectal 
carcinoma. European journal of surgical oncology : the journal of the European Society 
of Surgical Oncology and the British Association of Surgical Oncology, 345–347. 
Warnes, T. W., Hine, P., Kay, G., & Smith, A. (1981). Intestinal alkaline phosphatase in bile: 
evidence for an enterohepatic circulation. Gut, 493–498. 
83 
Saif, M. W., Alexander, D., & Wicox, C. M. (2005). Serum Alkaline Phosphatase Level as a 
Prognostic Tool in Colorectal Cancer: A Study of 105 patients. The journal of applied 
research, 88–95. 
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., . . . Johnson, D. H. 
(2006). aclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 
The New England journal of medicine, 2542–2550. 
Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 306–313. 
García-Teijido, P., Cabal, M. L., Fernández, I. P., & Pérez, Y. F. (2016). Tumor-Infiltrating 
Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. 
Oncology, 31–39. 
González-Cao, M., Karachaliou, N., Viteri, S., Morales-Espinosa, D., Teixidó, C., Sánchez Ruiz, 
J., . . . Rosell, R. (2015). Targeting PD-1/PD-L1 in lung cancer: current perspectives. 
Lung Cancer , 55–70. 
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Cancer, 
252–264. 
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., . . . Rimm, D. L. 
(2015). PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and 
Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer immunology research, 
326–332. 
Narayan, P., Wahby, S., Gao, J. J., Amiri-Kordestani, L., Ibrahim, A., Bloomquist, E., . . . 
Blumenthal. (2020). FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-
bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors 
Express PD-L1. Clinical cancer research : an official journal of the American 
Association for Cancer Research, 2284–2289. 
Gibson, R., Delaune, J., Szady, A., & Markham, M. (2016). Suspected autoimmune myocarditis 
and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung 
cancer. BMJ case reports, bcr2016216228. 
Bohling, S. D., & Allison, K. H. (2008). Immunosuppressive regulatory T cells are associated 
with aggressive breast cancer phenotypes: a potential therapeutic target. Modern 
pathology : an official journal of the United States and Canadian Academy of Pathology, 
Inc, 1527–1532. 
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006). Mechanisms of immune evasion by tumors. 
Advances in immunology, 51–81. 
Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001). A fresh look at tumor immunosurveillance 
and immunotherapy. Nature immunology, 293–299. 
84 
Kang, Y. K., Kang, W. K., Shin, D. B., Chen, J., Xiong, J., Wang, J., . . . McCloud, P. I. (2009). 
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with 
advanced gastric cancer: a randomised phase III noninferiority trial. Annals of oncology : 
official journal of the European Society for Medical Oncology, 666–673. 
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007). Immunosuppressive strategies 
that are mediated by tumor cells. Annual review of immunology, 267–296. 
Yale Medicine, S. (2021). Minimally Invasive Treatment for Metastatic Liver Cancers. Retrieved 
from Yale Medicine: https://www.yalemedicine.org/conditions/liver-cancer-minimally-
invasive-treatment 
Hoffman, R. M. (2015). Development of recombinant methioninase to target the general cancer-
specific metabolic defect of methionine dependence: a 40-year odyssey. Expert opinion 
on biological therapy, 21–31. 
Coalson, D. W., Mecham, J. O., Stern, P. H., & Hoffman, R. M. (1982). Reduced availability of 
endogenously synthesized methionine for S-adenosylmethionine formation in 
methionine-dependent cancer cells. Proceedings of the National Academy of Sciences of 
the United States of America, 4248–4251. 
Kaiser, P. (2020). Methionine Dependence of Cancer. Biomolecules, 568. 
Lim, H. I., Hamada, K., Yamamoto, J., Han, Q., Tan, Y., Choi, H. J., . . . Hoffman, R. M. (2020). 
Oral Methioninase Inhibits Recurrence in a PDOX Mouse Model of Aggressive Triple-
negative Breast Cancer. In vivo , 2281–2286. 
Han, Q., Tan, Y., & Hoffman, R. M. (2020). Oral dosing of Recombinant Methioninase Is 
Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer 
and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient. 
Anticancer research, 2813–2819. 
Kawaguchi, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Murakami, T., . . . Hoffman, R. M. (2019). 
Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-
Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. Cells, 410. 
Ito, Y., Oike, Y., Yasunaga, K., Hamada, K., Miyata, K., Matsumoto, S., . . . Suda, T. (2003). 
Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. 
Cancer research, 6651–6657. 
Kim, I., Kim, H. G., Kim, H., Kim, H. H., Park, S. K., Uhm, C. S., . . . Koh, G. Y. (2000). 
Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related 
protein that prevents endothelial-cell apoptosis. The Biochemical journal, 603–610. 
Santulli, G. (2014). Angiopoietin-like proteins: a comprehensive look. Frontiers in 
endocrinology, 4. 
85 
Koliwad, S. K., Gray, N. E., & Wang, J. C. (2012). Angiopoietin-like 4 (Angptl4): A 
glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte, 182–
187. 
Oike, Y., Akao, M., Yasunaga, K., Yamauchi, T., Morisada, T., Ito, Y., . . . Suda, T. (2005). 
Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nature 
medicine, 400–408. 
Xu, A., Lam, M. C., Chan, K. W., Wang, Y., Zhang, J., Hoo, R. L., . . . Lam, K. S. (2005). 
Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but 
induces hyperlipidemia and hepatic steatosis in mice. Proceedings of the National 
Academy of Sciences of the United States of America, 6086–6091. 
Lee, E. C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X. C., . . . Sonnenburg, W. K. 
(2009). Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and 
angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase 
(LPL). The Journal of biological chemistry, 13735–13745. 
Dijk, W., Heine, M., Vergnes, L., Boon, M. R., Schaart, G., Hesselink, M. K., . . . Kersten, S. 
(2015). ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during 
sustained cold exposure. eLife, e08428. 
Kersten, S., Lichtenstein, L., Steenbergen, E., Mudde, K., Hendriks, H. F., Hesselink, M. K., . . . 
Müller, M. (2009). Caloric restriction and exercise increase plasma ANGPTL4 levels in 
humans via elevated free fatty acids. Arteriosclerosis, thrombosis, and vascular biology, 
969–974. 
Tan, M. J., Teo, Z., Sng, M. K., Zhu, P., & Tan, N. S. (2012). Emerging roles of angiopoietin-
like 4 in human cancer. Molecular cancer research : MCR, 677–688. 
Grootaert, C., Van de Wiele, T., Verstraete, W., Bracke, M., & Vanhoecke, B. (2012). 
Angiopoietin-like protein 4: health effects, modulating agents and structure-function 
relationships. Expert review of proteomics, 181–199. 
Lei, X., Shi, F., Basu, D., Huq, A., Routhier, S., Day, R., & Jin, W. (2011). Proteolytic 
processing of angiopoietin-like protein 4 by proprotein convertases modulates its 
inhibitory effects on lipoprotein lipase activity. The Journal of biological chemistry, 
15747–15756. 
Yau, M. H., Wang, Y., Lam, K. S., Zhang, J., Wu, D., & Xu, A. (2009). highly conserved motif 
within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its 
inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. The 
Journal of biological chemistry, 11942–11952. 
Galaup, A., Cazes, A., Le Jan, S., Philippe, J., Connault, E., Le Coz, E., . . . Germain, S. (2006). 
Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and 
tumor cell motility and invasiveness. Proceedings of the National Academy of Sciences of 
the United States of America, 18721–18726. 
86 
Kim, S. H., Park, Y. Y., Kim, S. W., Lee, J. S., Wang, D., & DuBois, R. N. (2011). ANGPTL4 
induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer 
progression. Cancer research, 7010–7020. 
Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. 
(2008). GFbeta primes breast tumors for lung metastasis seeding through angiopoietin-
like 4. Cell, 66–77. 
Zhu, P., Tan, M. J., Huang, R. L., Tan, C. K., Chong, H. C., Pal, M., . . . Tan, N. S. (2011). 
Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and 
confers anoikis resistance to tumors. Cancer cell, 401–415. 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 646–
674. 
La Paglia, L., Listì, A., Caruso, S., Amodeo, V., Passiglia, F., Bazan, V., & Fanale, D. (2017). 
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through 
PPAR Signaling Pathway. PPAR research, 8187235. 
Li, F., Sonveaux, P., Rabbani, Z. N., Liu, S., Yan, B., Huang, Q., . . . Li, C. Y. (2007). 
Regulation of HIF-1alpha stability through S-nitrosylation. Molecular cell, 63–74. 
Hu, K., Babapoor-Farrokhran, S., Rodrigues, M., Deshpande, M., Puchner, B., Kashiwabuchi, F., 
. . . Sodhi, A. (2016). Hypoxia-inducible factor 1 upregulation of both VEGF and 
ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. 
Oncotarget, 7816–7828. 
Mathieu, M., Iampietro, M., Chuchana, P., Guérit, D., Djouad, F., Noël, D., & Jorgensen, C. 
(2014). Involvement of angiopoietin-like 4 in matrix remodeling during chondrogenic 
differentiation of mesenchymal stem cells. The Journal of biological chemistry, 8402–
8412. 
Girroir, E. E., Hollingshead, H. E., Billin, A. N., Willson, T. M., Robertson, G. P., Sharma, A. 
K., . . . Peters, J. M. (2008). Peroxisome proliferator-activated receptor-beta/delta 
(PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell 
lines. Toxicology, 236–243. 
Dong, D., Jia, L., Zhou, Y., Ren, L., Li, J., & Zhang, J. (2017). Serum level of ANGPTL4 as a 
potential biomarker in renal cell carcinoma. Urologic oncology, 279–285. 
Nakayama, T., Hirakawa, H., Shibata, K., Nazneen, A., Abe, K., Nagayasu, T., & Taguchi, T. 
(2011). Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: 
ANGPTL4 promotes venous invasion and distant metastasis. Oncology reports, 929–935. 
Dao, T., Gapihan, G., Leboeuf, C., Hamdan, D., Feugeas, J. P., Boudabous, H., . . . Bousquet, G. 
(2020). Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases 
risk of brain metastases in women with breast cancer. Oncotarget, 1590–1602. 
87 
Gong, X., Hou, Z., Endsley, M. P., Gronseth, E. I., Rarick, K. R., Jorns, J. M., . . . Wang, L. 
(2019). Interaction of tumor cells and astrocytes promotes breast cancer brain metastases 
through TGF-β2/ANGPTL4 axes. NPJ precision oncology, 24. 
Zhao, J., Liu, J., Wu, N., Zhang, H., Zhang, S., Li, L., & Wang, M. (2020). ANGPTL4 
overexpression is associated with progression and poor prognosis in breast cancer. 
Oncology letters, 2499–2505. 
Wang, L., Cossette, S. M., Rarick, K. R., Gershan, J., Dwinell, M. B., Harder, D. R., & 
Ramchandran, R. (2013). Astrocytes directly influence tumor cell invasion and metastasis 
in vivo. PloS one, e80933. 
Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., . . . Massagué, J. 
(2009). Genes that mediate breast cancer metastasis to the brain. Nature, 1005–1009. 
Desgrosellier, J. S., & Cheresh, D. A. (2010). Integrins in cancer: biological implications and 
therapeutic opportunities. Nature reviews, 9–22. 
Liao, Y. H., Chiang, K. H., Shieh, J. M., Huang, C. R., Shen, C. J., Huang, W. C., & Chen, B. K. 
(2017). Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and 
tumour metastasis in head and neck squamous cell carcinoma. Oncogene, 2228–2242. 
Terada, L. S., & Nwariaku, F. E. (2011). Escaping Anoikis through ROS: ANGPTL4 controls 
integrin signaling through Nox1. Cancer cell, 297–299. 
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008). The impact of O2 availability on human 
cancer. Cancer, 967–975. 
Le Jan, S., Amy, C., Cazes, A., Monnot, C., Lamandé, N., Favier, J., . . . Germain, S. (2003). 
Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in 
conventional renal cell carcinoma. The American journal of pathology, 1521–1528. 
Zhang, H., Wong, C. C., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., . . . Semenza, G. 
L. (2012). HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates 
vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene, 1757–1770. 
Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and 
therapeutics. Oncogene, 625–634. 
Semenza, G. L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell, 399–408. 
Kaelin, W. G. (2005). ROS: really involved in oxygen sensing. Cell metabolism, 357–358. . 
Fuchs, M., Gerber, J., Drapkin, R., Sif, S., Ikura, T., Ogryzko, V., . . . Livingston, D. M. (2001). 
The p400 complex is an essential E1A transformation target. Cell, 297–307. 
88 
Samuelson, A. V., Narita, M., Chan, H. M., Jin, J., de Stanchina, E., McCurrach, M. E., . . . 
Lowe, S. W. (2005). p400 is required for E1A to promote apoptosis. The Journal of 
biological chemistry, 21915–21923. 
Kimura, A., & Horikoshi, M. (1998). Tip60 acetylates six lysines of a specific class in core 
histones in vitro. Genes to cells : devoted to molecular & cellular mechanisms, 789–800. 
Legube, G., Linares, L. K., Lemercier, C., Scheffner, M., Khochbin, S., & Trouche, D. (2002). 
Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after 
UV irradiation. The EMBO journal, 1704–1712. 
Sun, Y., Jiang, X., & Price, B. D. (2010). Tip60: connecting chromatin to DNA damage 
signaling. Cell cycle, 930–936. 
Halkidou, K., Gnanapragasam, V. J., Mehta, P. B., Logan, I. R., Brady, M. E., Cook, S., . . . 
Robson, C. N. (2003). Expression of Tip60, an androgen receptor coactivator, and its role 
in prostate cancer development. Oncogene, 2466–2477. 
Gorrini, C., Squatrito, M., Luise, C., Syed, N., Perna, D., Wark, L., . . . Lough, J. (2007). Tip60 
is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage 
response. Nature, 1063–1067. 
Squatrito, M., Gorrini, C., & Amati, B. (2006). Tip60 in DNA damage response and growth 
control: many tricks in one HAT. Trends in cell biology, 433–442. 
Chevillard-Briet, M., Quaranta, M., Grézy, A., Mattera, L., Courilleau, C., Philippe, M., . . . 
Escaffit, F. (2014). Interplay between chromatin-modifying enzymes controls colon 
cancer progression through Wnt signaling. Human molecular genetics, 2120–2131. 
Mattera, L., Escaffit, F., Pillaire, M. J., Selves, J., Tyteca, S., Hoffmann, J. S., . . . Trouche, D. 
(2009). The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through 
DNA damage response pathways. Oncogene, 1506–1517. 
Zhao, H., Jin, S., & Gewirtz, A. M. (2012). The histone acetyltransferase TIP60 interacts with c-
Myb and inactivates its transcriptional activity in human leukemia. The Journal of 
biological chemistry, 925–934. 
Idrissou, M., Boisnier, T., Sanchez, A., Khoufaf, F., Penault-Llorca, F., Bignon, Y. J., & 
Bernard-Gallon, D. (2020). TIP60/P400/H4K12ac Plays a Role as a Heterochromatin 
Back-up Skeleton in Breast Cancer. Cancer genomics & proteomics, 687–694. 
Stacy, A. J., Zhang, J., Craig, M. P., Hira, A., Dole, N., & Kadakia, M. P. (2019). TIP60 up-
regulates ΔNp63α to promote cellular proliferation. The Journal of biological chemistry, 
17007–17016. 
Fedele, P., Orlando, L., & Cinieri, S. (2017). Targeting triple negative breast cancer with histone 
deacetylase inhibitors. Expert opinion on investigational drugs, 1199–1206. 
89 
Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-
Burow, B. M. (2012). Targeting triple-negative breast cancer cells with the histone 
deacetylase inhibitor panobinostat. Breast cancer research : BCR, R79. 
Golias, C. H., Charalabopoulos, A., & Charalabopoulos, K. (2004). Cell proliferation and cell 
cycle control: a mini review. International journal of clinical practice, 1134–1141. 
Williams, G. H., & Stoeber, K. (2012). The cell cycle and cancer. The Journal of pathology, 
352–364. 
Barr, A. R., & Gergely, F. (2007). Aurora-A: the maker and breaker of spindle poles. Journal of 
cell science, 2987–2996. 
Fu, J., Bian, M., Jiang, Q., & Zhang, C. (2007). Roles of Aurora kinases in mitosis and 
tumorigenesis. Molecular cancer research : MCR, 1–10. 
Vader, G., & Lens, S. M. (2008). The Aurora kinase family in cell division and cancer. 
Biochimica et biophysica acta,, 60–72. 
Dar, A. A., Belkhiri, A., & El-Rifai, W. (2009). The aurora kinase A regulates GSK-3beta in 
gastric cancer cells. Oncogene, 866–875. 
Sen, S., Zhou, H., Zhang, R. D., Yoon, D. S., Vakar-Lopez, F., Ito, S., . . . Czerniak, B. (2002). 
Amplification/overexpression of a mitotic kinase gene in human bladder cancer. Journal 
of the National Cancer Institute, 320–1329. 
Tanaka, T., Kimura, M., Matsunaga, K., Fukada, D., Mori, H., & Okano, Y. (1999). Centrosomal 
kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer 
research, 2041–2044. 
Klein, A., Flügel, D., & Kietzmann, T. (2008). Transcriptional regulation of serine/threonine 
kinase-15 (STK15) expression by hypoxia and HIF-1. Molecular biology of the cell, 
3667–3675. 
Lehman, N. L., O'Donnell, J. P., Whiteley, L. J., Stapp, R. T., Lehman, T. D., Roszka, K. M., . . . 
Poisson, L. M. (2012). Aurora A is differentially expressed in gliomas, is associated with 
patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. 
Cell cycle (Georgetown, Tex.), 489–502. 
Fanale, D., Bazan, V., Corsini, L. R., Caruso, S., Insalaco, L., Castiglia, M., . . . Russo, A. 
(2013). HIF-1 is involved in the negative regulation of AURKA expression in breast 
cancer cell lines under hypoxic conditions. Breast cancer research and treatment, 505–
517. 
Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D. H., Zhu, F., . . . 
Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition 
Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and 
90 
Neck. Clinical cancer research : an official journal of the American Association for 
Cancer Research, 3430–3442. 
Huang, R. L., Teo, Z., Chong, H. C., Zhu, P., Tan, M. J., Tan, C. K., . . . Tan, N. S. (2011). 
ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of 
intercellular VE-cadherin and claudin-5 clusters. Blood, 3990–4002. 
Verine, J., Lehmann-Che, J., Soliman, H., Feugeas, J. P., Vidal, J. S., Mongiat-Artus, P., . . . 
Germain, S. (2010). Determination of angptl4 mRNA as a diagnostic marker of primary 
and metastatic clear cell renal-cell carcinoma. PloS one, e10421. 
Cazes, A., Galaup, A., Chomel, C., Bignon, M., Bréchot, N., Le Jan, S., . . . Monnot, C. (2006). 
Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, 
migration, and sprouting and alters actin cytoskeleton. Circulation research, 1207–1215. 
Idowu, M. O., Kmieciak, M., Dumur, C., Burton, R. S., Grimes, M. M., Powers, C. N., & 
Manjili, M. H. (2012). CD44(+)/CD24(-/low) cancer stem/progenitor cells are more 
abundant in triple-negative invasive breast carcinoma phenotype and are associated with 
poor outcome. Human pathology, 364–373. 
Bailey, T. A., Luan, H., Tom, E., Bielecki, T. A., Mohapatra, B., Ahmad, G., . . . Band, H. 
(2014). A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling 
of ErbB2 in breast cancer cells. The Journal of biological chemistry, 30443–30458. 
Simeon, J. (2017). Characterization of Angiopoietin-Like 4 Dependent Triple Negative Breast 
Cancer Cells Extravasation Using An In Vitro Model of The Human Blood Brain Barrier. 
University of Arkansas, Honors College, Fulbright College.  
Simeon, J., Thrush, J., & Bailey, T. (2021). Angiopoietin-like protein 4 is a chromatin-bound 
protein that enhances mammosphere formation in vitro and experimental triple-negative 
breast cancer brain and liver metastases in vivo. Journal of Carcinogenesis. 
McGuire, A., Casey, M. C., Shalaby, A., Kalinina, O., Curran, C., Webber, M., . . . Brown, J. 
(2019). Quantifying Tip60 (Kat5) stratifies breast cancer. Scientific reports, 3819. 
Gao, C., Bourke, E., Scobie, M., Famme, M. A., Koolmeister, T., Helleday, T., . . . Brown, J. A. 
(2014). Rational design and validation of a Tip60 histone acetyltransferase inhibitor. 
Scientific reports, 5372. 
van Beekum, O., Brenkman, A. B., Grøntved, L., Hamers, N., van den Broek, N. J., Berger, R., . 
. . Kalkhoven, E. (2008). The adipogenic acetyltransferase Tip60 targets activation 
function 1 of peroxisome proliferator-activated receptor gamma. Endocrinology, 1840–
1849. 
Sapountzi, V., Logan, I. R., & Robson, C. N. (2006). Cellular functions of TIP60. The 
international journal of biochemistry & cell biology, 1496–1509. 
91 
Dietze, E. C., Chavez, T. A., & Seewaldt, V. L. (2018). Obesity and Triple-Negative Breast 
Cancer: Disparities, Controversies, and Biology. The American journal of pathology, 
280–290. 
Kolb, R., Kluz, P., Tan, Z. W., Borcherding, N., Bormann, N., Vishwakarma, A., . . . Zh. (2019). 
Obesity-associated inflammation promotes angiogenesis and breast cancer via 
angiopoietin-like 4. Oncogene, 2351–2363. 
Sun, H., Zou, J., Chen, L., Zu, X., Wen, G., & Zhong, J. (2017). Triple-negative breast cancer 
and its association with obesity. Molecular and clinical oncology, 935–942. 
Ness, C., Garred, Ø., Eide, N. A., Kumar, T., Olstad, O. K., Bærland, T. P., . . . Noer, A. (2017). 
Multicellular tumor spheroids of human uveal melanoma induce genes associated with 
anoikis resistance, lipogenesis, and SSXs. Molecular vision, 680–694. 
Li, T. Y., Song, L., Sun, Y., Li, J., Yi, C., Lam, S. M., . . . Lin, S. C. (2018). Tip60-mediated 
lipin 1 acetylation and ER translocation determine triacylglycerol synthesis rate. Nature 
communications, 1916. 
Tang, C. (n.d.). In vitro vs. In vivo: Is One Better? Retrieved from uhnresearch: 
https://www.uhnresearch.ca/news/vitro-vs-vivo-one-better 
Vandamme, T. F. (2014). Use of rodents as models of human diseases. Journal of pharmacy & 
bioallied sciences, 2–9. 
Lee, J., Bayarsaikhan, D., Bayarsaikhan, G., Kim, J. S., Schwarzbach, E., & Lee, B. (2020). 
Recent advances in genome editing of stem cells for drug discovery and therapeutic 
application. Pharmacology & therapeutics, 107501. 
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C., Voduc, D., Speers, C. H., . . . 
Gelmon, K. (2010). Metastatic behavior of breast cancer subtypes. ournal of clinical 
oncology : official journal of the American Society of Clinical Oncology, 3271–3277. 
Rikhi, R., Wilson, E. M., Deas, O., Svalina, M. N., Bial, J., Mansoor, A., . . . Keller, C. (2016). 
Murine model of hepatic breast cancer. Biochemistry and biophysics reports, 1–5. 
Lim, H. I., Yamamoto, J., Han, Q., Sun, Y. U., Nishino, H., Tashiro, Y., . . . Hoffman, R. M. 
(2020). Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant 
Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model. In vivo (Athens, 
Greece), 3163–3169. 
Wettersten, H. I., Ganti, S., & Weiss, R. H. (2014). Metabolomic profiling of tumor-bearing 
mice. Methods in enzymology, 275–296. 
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., . . . Nakahata, T. 
(2002). NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for 
engraftment of human cells. Blood, 3175–3182. 
92 
Berman, A. T., Thukral, A. D., Hwang, W. T., Solin, L. J., & Vapiwala, N. (2013). Incidence and 
patterns of distant metastases for patients with early-stage breast cancer after breast 
conservation treatment. Clinical breast cancer, 88-94. 
Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., & Puglisi, F. 
(2015). Pattern of metastasis and outcome in patients with breast cancer. Clinical & 
experimental metastasis, 125–133. 
Soares, K. C., Foley, K., Olino, K., Leubner, A., Mayo, S. C., Jain, A., . . . Zheng, L. (2014). A 
preclinical murine model of hepatic metastases. Journal of visualized experiments : 
JoVE, 51677. 
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., . . . 
Massagué, J. (2003). A multigenic program mediating breast cancer metastasis to bone. 
Cancer cell, 537–549. 
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., . . . Massagué, J. 
(2005). Genes that mediate breast cancer metastasis to lung. Nature, 518–524. 
Basse, P., Hokland, P., Heron, I., & Hokland, M. (1988). Fate of tumor cells injected into left 
ventricle of heart in BALB/c mice: role of natural killer cells. . Journal of the National 
Cancer Institute, 657–665. 
Aslakson, C. J., & Miller, F. R. (1992). Selective events in the metastatic process defined by 
analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. 
Cancer research, 1399–1405. 
Dexter, D. L., Kowalski, H. M., Blazar, B. A., Fligiel, Z., Vogel, R., & Heppner, G. H. (1978). 
Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer research, 
3174–3181. 
Doornebal, C. W., Klarenbeek, S., Braumuller, T. M., Klijn, C. N., Ciampricotti, M., Hau, C. S., 
. . . de Visser, K. E. (2013). A preclinical mouse model of invasive lobular breast cancer 
metastasis. Cancer research, 353–363. 
Derksen, P. W., Liu, X., Saridin, F., van der Gulden, H., Zevenhoven, J., Evers, B., . . . Jonkers, 
J. (2006). Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular 
mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer 
cell, 437–449. 
Fantozzi, A., & Christofori, G. (2006). Mouse models of breast cancer metastasis. Breast cancer 
research : BCR, 212. 
Gómez-Cuadrado, L., Tracey, N., Ma, R., Qian, B., & Brunton, V. G. (2017). Mouse models of 
metastasis: progress and prospects. Disease models & mechanisms, 1061–1074. 
Munoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., & Kerbel, R. S. (2006). 
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer 
93 
using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer 
research, 3386–3391. 
Yang, W. H., Huang, Z., Wu, J., Ding, C. C., Murphy, S. K., & Chi, J. T. (2020). A TAZ-
ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in 
Epithelial Ovarian Cancer. Molecular cancer research : MCR, 79–90. 
García-Teijido, P., Cabal, M. L., Fernández, I. P., & Pérez, Y. F. (2016). Tumor-Infiltrating 
Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. 
Oncology, 31–39. 
Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y. C., von Wahlde, M. K., . . . 
Pusztai, L. (2018). Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and 
Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy 
Trial. Molecular cancer therapeutics, 1324–1331. 
Mills, C. D. (2012). M1 and M2 Macrophages: Oracles of Health and Disease. Critical reviews 
in immunology, 463–488. 
Mills, C. D., Lenz, L. L., & Harris, R. A. (2016). A Breakthrough: Macrophage-Directed Cancer 
Immunotherapy. Cancer research, 513–516. 
Aryal, B., Rotllan, N., Araldi, E., Ramírez, C. M., He, S., Chousterman, B. G., . . . Fernández-
Hernando, C. (2016). ANGPTL4 deficiency in haematopoietic cells promotes monocyte 
expansion and atherosclerosis progression. Nature communications, 12313. 
Verma, S., Provencher, L., & Dent, R. (2011). Emerging trends in the treatment of triple-
negative breast cancer in Canada: a survey. Current oncology (Toronto, Ont.), 180–190. 
 
 
 
 
 
 
 
 
 
 
94 
VI. APPENDIX 
 
